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Abstract 
Cancer i::. one of the leading causes of deaths in the world. Vast majority of 
contemporary cancer therapies have s ide effects. Dietmy plants and plant-based products 
hmc been sho\\ n to reduce the'cverity of  the condit ion with minimal  or no ide effects. 
HO'wcvcr, the preci e molecular interact ions that lead to this are largely unknown.  In th is  
stud) , evcral target proteins in cancer pathways were chosen and a col lect ion of 
chcmicals  derived from plant , or phytochemicals ,  were v irtua l ly  screened in silica using 
molecular docking teclmiques. Furthermore, the docking modes \\ ere SUbjected to 
extended mole u lar dynamics ( M D) s imulations. The pham1acokinet ic propert ies of these 
phytochemicals were a l  0 checked using in silica predict ion teclmiques. A short l i s t  of 
phytochemicals were identi fied, inc luding e l 1agic acid, macrocarpal A,  cpigal locatecbin 
gal l ate and quercet in ,  which appeared to b ind to the protein Rab5A, a GTPase involved in 
i ntrace l l u lar membrane trafficking.  MD s imulat ions also produced stable interactions 
betv;cen the protein and the l igands. These molecules a lso showed an acceptable dmg 
s ore and cou ld  therefore be subjected to further val idation. 
Keywords: Tn silica, Molecular Docking, MD S imulat ion, EGFR, Rab5A.  
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Chapter 1: Introduction 
1.1 \"hat is cancel''? 
A fine balance between cel l  prol i ferat ion and cel l  death maintal l1s organisms. If 
th i  homcosta i s  i s  disturbed by tress, decrease in cel l death or increase in  prol i feration 
rate, a tumor m ight occur, which can further progress in to a cancer. 
Tumor de\ e lopment is most commonly described as natural selection fol lowed by c lonal 
expan ion, rcult ing in  monoclonal tumors orig inat ing from the progeny of a s ingle cel l  
( owel L  1 976). 
Aberrations that confer growth advantages to the ce l l  w i l l  accumulate during the 
c lonal selection process. These changes are consequences of d i fferent processes: 1 )  
act ivat ion of proto-oncogenes rendering the gene constitutively act ive or active under 
condi t ions in which the wi ld  type gene is not, 2)  inactivation of tumor suppressor genes, 
reducing  or abol ish ing the act iv i ty of the gene product ,  and 3) a l teration of repai r  genes, 
which nom1a l ly  keep genetic  a lterations to a min imum. Genomic analyses focusing on 
structural and numerical aberrations of chromosomes have long suggested that cancer 
could have a genetic component (Vogels te in  & Kinzler, 2004) . 
Ev idence indicates that tumors of variou type often derive d irectly from the 
normal  t i ssues in which they are first d iscovered. However, tumors are capable of 
moving wi th in the confines of the human body. In many patients multiple tumors were 
d i scovered at anatomIcal s ites quite dIstant from where the disease first began, a 
consequence of the tendency of cancers to spread thought thc body and to establ i sh ne\v 
colonies or cancer ce l ls, a process ca l l ed metastaSIS (Figure J.1). Metastas is is oftcn 
traceabl directly back to the ite where the di ea e had begun (the primary tumor). 
(Wemberg, 2013) 
Figure 1.1: Metasta es of cancer cel ls in the lung of 
two mice 
1.1.1  Causes of cancer 
Cancer i s  the result of cell that uncontro1 lably grow and do not die. Nonna! cells 
III the body fol low an orderly path of growth, division, and death. Apoptosis i s  
programmed cell death and when this process breaks down, cancer begins to fonn. 
Unlike regular cells, cancer cells do not experience programmatic death and instead 
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continue to grow and divide. This  lead to a mas of abnonnal cel ls  that grows out of 
control .  Cancer can be the result of many causes including genetic predisposition that i s  
inherited from fami ly members. It is possible to  be born with certain genetic mutations or 
a fault in a gene that makes an individual statistical ly more l i kely to develop cancer later 
in l ife. 
Another cause is the age. There is an increase in the number of possible cancer-
causing mutations in our DNA as one ages . This makes age an important risk factor for 
cancer. Several viruses have also been l inked to cancer such as: human papil lomavirus, 
hepatIti B and C and Ep tem-Barr \lruS. Human immunodeficiency virus (HIV) and 
anything el e that uppresse or weaken the immune system, because It inhibits the 
body' abi ltty LO fight mfections, mcreases the chance of developing cancer. 
Carcmogen arc ubstances that are directly responsible for damaging D A, 
promotmg or aiding cancer. Tobacco, a bestos, ar enic, radiation such as gamma and X­
ray , the sun, and compounds in car exhaust fumes are al l examples of carcinogens. 
When our bodies are expo ed to carcinogens, free radicals are formed that removes 
electron from other molecule in the body. These free radicals damage cells and affect 
their abi l i ty to function normal ly. 
1.1.2 Medicinal Plant and Cancer 
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Medicinal plants have been u ed for the treatment of various diseases from 
ancient times. The anticancer properties of plants have been recognized for centuries. 
Plant-based drugs with potent anticancer effects should add to the efforts to find a cheap 
drug with hmited c linical side effects. 
The ational Cancer Institute (NCI) has screened approximately 35,000 plant 
pecies for potential anticancer activities. Among them, about 3,000 plant species have 
demonstrated reproducible anticancer activity (data available at http://www.ars­
grin.gov/duke 
Many tudies have focused on the chemoprotective properties of plants such as 
anticarcinogenic properties of Abrus precatorius on Yoshida sarcoma in rats, 
fibrosarcoma in mice and asci tes tumor cells ( Reddy et ai, 1 969). Similarly, Dhar and 
colleagues have examined the anticancer propert ies of Albizzia lebbeck on sarcoma in 
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TnlCC and A lstonia scholarieson bcnzo[aJpyrene-induced forestomach carCl110ma III 
humans ( Dhar ct a l .  1968) .  
Other pl ants that hm c shown anticarc inogcntc propert ies include Al7acardiZln1 
occidentale i n  hepatoma, Asparagus rac emosa III human epidcnnoid 
carc inoma, Bo.m·e/lta serrata in human cpide1111al carc inoma of the 
na opharynx, Erlhyrina sliberosa in sarcoma, Ellphorbia hirta in Freund VIruS 
leuKemia,  G) '/1ondropis pentaphylla in hepatoma, igella 
carc inoma, Peaderia foetic/a i n  human epidermoid 
salim i n  Lewis 
carc i lloma of 
lung 
the 
na opharynx,  Picrorrlii:::a kUlToa in hepat ic cancers, and Withania sotllnifera in various 
tumors ( Dhar et a!, 1 968). 
The ant icancer character ist ics of a number of p lants are st i l l  being actively 
researched and some have shown promis ing resu l ts .  Some plants and p lant products that 
have shown promise as anticancer agents are d i scussed in  deta i l  in  the fol lowing sections. 
A l though many b ioact ive plant chemicals have been ident ified very l it t le  i s  known about 
the preci se molecular mechanisms in the prevention of cancer. 
1.2 Problem statement 
The purpose of th is  s tudy was to ident ify how a coUect ion of plant chemicals 
( P hylochemicals)  may interact with proteins i n  cancer pathways. U nderstanding the 
preci se mechanism of how the e compounds interact with their target could be of benefit 
in developing novel cancer therapies .  Morco\ er,  the results could lead to the 
devclopment of spec i fic phytochemical bascd treatments that havc fewer s ide effects for 
patients. I denti fication or potent ial drug� could also hm C Sign ificant commercial  benefi ts .  
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1 .3 Object ives 
In th is  stud}, a col l ection of natura l  molecules was screened in silica to identify i f  
the} could i nteract wi th major proteins  in  d i fferent cancer pathways. The mam obj ectives 
or th is  study v ,  ere : 
1. To select a l i st of  phytochemicals that has been shown to have an effect on cancer. 
2. To obta in  a l i st of protcins  that can be used as drug targets. 
3. To perfom1 in 'Iilica screening to obtain a ShOli l i st of candidate molecules that could 
be used for cancer therapy. 
These object ives were addressed il1 silica using molecular docking and molecular 
dynamic s imulat ion s tudy. This  approach has the potentia l  to generate a wea l th of 
infonnation on effects of these compounds on cancer pathways, which wi l l  help to 
expla in the mechani sms of actioll .  
This thesi s  focused on s ixty-seven plant compounds that are known to be able to 
protect against  cancer development. Seven d ifferent target prote ins,  which are currently 
targets for cancer treatment, were chosell . This inc luded serine-threonine protein k inase 1 
(AKT l ), cyc l i n  dependent k inase 2 (CDK2 ) ,  epidennal growth factor receptor (EGFR), 
extracel lular s ignal regulated k inase 2 (ERK1) .  janus kinase 1 (JAK l ) , mi togen act ivated 
protein k ina e k inase 1 ( M A P K K I )  and Ras-related protein 5A ( Rab5A). 
Chapter 2: Review of literature 
anccr i s  the third lead ing cause of death in the UAE.  A retro pective analy i s  
of  pat ients admI tted to Tawam I10spital during year 1 980 to 1 984 indicated the presence 
of 1 ,357 ca c of cancer. Thcse inc luded breast cancer (9%), head and neck cancer (9%), 
lung cancer ( 7%), nOll- llodgk in lymphoma (6%), acute leukemia ( 5%), cancer of the 
cen i x  (5° 0) ,  stomach cancer (5%), H odgk ins lymphoma (40/0). cancers of the colon and 
rectum (4%), thy roid cancer (4%), and others. ( Holt ,  1 985)  
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fost cancers i nvolve se\'eral important pathways that regulate d i fferent cel lular 
proces cs uch a ce l l  fate, cel l urv ival  and genome maintenance. The driver genes, 
WhICh are responsible for the formation of tumors, function through these s ignal ing 
pathway . 
2. 1 Cancel" Pathways 
Several s igna l i ng molecules that play a cri t ical  rol e  i n  cancer pathways have been 
i denti fied and are now recognized as potent ia l  therapeutic target .  One of the most 
i mportant pathways is the Epidermal Growth Factor Receptor (EGF R) pathway . Thi s  
pathwa) exists o n  the ce l l  surface and n0n11al ly helps the ce l l s  to grow and divide. Upon 
s t imulat ion of EGFR,  an extensive network of s ignal  transduct ion pathways is act ivated, 
resu l t  in autophosphory lation of key tyros ine residues. These tyrosine pho phorylated 
si tes l ead to the actintion of downstream signal ing cascades inc lud ing the RAS/ERK 
pathway, 1APK;ERK pathway, the phosphatidyl inositol 3-k inase (P13 K)/ AKT pathway 
and the Janus k l l1ase, S ignal transducer and ac tivator of transcription (JAK! STAT) 
pathway. These pathways act in a coord inated manner to promote cel l  sun ivaI . 
These transmembrane prote ins are actIvated fol lowing the binding with pept ide 
growth factors of the EGF-fami ly of proteins .  The abi l ity of cel l s  to sense their 
em i ronment and decide to sun'i v e  or d ie  i s  dependent largely upon gro\\ih factors . 
EGFR i s  a key growth factor regulat ing cel l  survival found on the surface of  ce l l s .  
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EGFR p Ia) an imp0l1ant ro le  in epithe l ia l  cel l  function. I n  breast cancer, the EGF 
receptor, ERBB? can be ampl ified and over-expressed and th is  i s  associated with poor 
prognosi and drug re i tance (Henson et a I . ,  2007). 
EGFR has been shown to be frequent ly overexpressed or hyper activated in  a 
number of  epi the l ia l  tumors. F igure  2 . 1 shows downstream s igna l i ng pathways regulated 
b) EGFR (Nyati et a l . ,  2006). 
The downstream s ignal i ng effects of these aberrations l ead to impaired apoptosis ,  
and or enhanced pro l i feration, angiogenes is .  necros is, and treatment refractoriness, 
suggesting  a causative re lat ionship between receptor dysregulat ion and the pathobiology 
of man) cancers (Taylor et a I . ,  20 1 2) .  
lon , ,,  '11,(.·  I' ,1.1 ..., n<J C,ro"f 
N.atu ... Reviews C m 
Figure 2 . 1 :  The main downstream signaling pathways regulated by EGFR 
2 . 1.2 RaslERK Pathway 
EGF activate the ERK pathway through the binding of Grb2 or Shc to 
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phosphorylated ErbB receptors, which in tum results in the recruitment of the son of 
evenless (SOS) to the activated receptor dimer ( Henson and Gibson, 2006).  SOS then 
activates RAS leading to the activation of RAF - 1 . RAF - 1  subsequently 
phosphorylates MEK I and MEK2,  which activate respectively ERK I and E RK2 . 
This pathway results in cell proliferation and in the increased transcription of Bcl-2 
family members and inhibitor of apoptosis proteins (lAPs), thereby promoting cell 
survival . Growth factors and mitogens use the RasIRaflMEKIERK signaling cascade to 
transmit signals from their receptors to regulate gene expression and prevent apoptosis. 
Abnormal activation of this pathway occurs in human cancer due to mutations at upstream 
membrane reccptoL and Ras and B-Raf as wel l  as genes in other pathways, which erve 
to regu late Raf act iv ity ( 1cCubrey ct a! ,  2007) .  
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The Ra::. pathway is a s ignal tran ductlOI1 cascade. Ras ( rat sarcoma) prote i ns are 
one of the 1110'[ \ve l l  studied oncoproteins and arc a major component of the OS-Ras­
Raf- 1 A P  k ina e mi togen ic cascade. About 25% of human tumors and 90% of a l l  
pancreat ic  tumor have a mutant f0l111 of the i ntracel l u lar signa l ing molecule Ras (a small  
GTP bmding s ignal ing molecule) .  Ra proteins bind to GOP in an inactive state but upon 
s tmmlat lon through GEFs (guanine nucleotide exchanges factors) are act ivated by b inding 
to GTP (F igure 2 . 1 ) . Active Ras functions as GTPase througb GAPs (GTPase-ac tivating 
proteins),  which hydrolyse the GTP and reach the inact ive state (Hejmadi ,  20 1 0) .  
RAS oncogene have been original ly  di scovered as retroviral oncogenes, and ever 
i nce const i tut i\  ely act ivat ing RAS mutations have been ident i fied in  human tumors, tbey 
are the focus of i ntense research (Raja l i ngam et a I . ,  2007). 
I n  tumors, typical ly,  a s ingle poi nt mutat ion t ransforms the n0l111al Ras into a Ras 
oncoprotein,  in \\ h ich the GTPase activ i ty is lost, leading to a constantly act ive Ras and a 
cancer ce l l  that cannot tum off i t s  pro l i ferat ion status (Hejmadi ,  20 1 0) .  A l temati\ ely,  Ras 
act ivat ion pathways may be d i s tu rbed ei ther due to oncoprotein or mutations in regu la tory 
pathways (as shown i n  F igure 2 . 2 ) .  
membrane receptors and Ras and B-Raf a wel l  as genes in other pathways, which serve 
to regu late Raf act iv I ty ( McCubrey et aL 2007).  
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Figure 2 .2 :  Changes in Ras signal ing 
Ras is i ta l  in several signal ing pathways and it acts as a binary switch. B inding 
GDP (guanine nucleotide dipho pate) in an inactive state and GTP (guanine nucleotide 
tripho pate) in its active state when it stimulates GF signal ing. Inactivate Ras is activated 
by GEF (guanine nucleotide exchange factor) by exchanging i ts GDP for GTP. This step 
IS short l ived because Ras ha an intrinsic GTPase activity, which means that it 
hydrolyses GTP to GDP. Mutations or oncoproteins that block the GTPase function 
restrict Ras in a permanently active, signaling state. (Hejmadi, 20 1 0) 
The Rab family i s  part of the Ras superfamily of small  GTPases. There are at least 
60 Rab genes in the human genome. The different Rab GTPases are localized to the 
cytosolic face of specific intracel lular membranes, where they function as regulators of 
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d lstmct steps 1 11 membrane traffic pathways. Their ce l l u lar oncogenes were ident ified i n  
humans and their mutations ""cre found i n  some human carC l l10mas. ( Hutagalung & 
o\ ick .  20 1 1 ) .  They ha\ e been impl icated in the progression of mult ip le cancers as 
membrane traffic plays a sign i ficant ro le in cancer biology, primari ly in  the loss of cell 
polarity and 1 11 the metastatic tranSf0n11at Jon of  tumor cel l s  ( Hutagalung & Novick, 20 1 1 ) . 
Rab5A IS one of the important Rab subfami ly members, a regu latory guanos ine 
triphosphatase that i associated wi th the transport and fusion of endocytic vesicles, and 
pali lc ipate in regulat ion of intracel l u lar s ignal ing pathways that a l low ce l ls  to adapt to the 
speci fic environment. Recently, i t  ha been reported that the Rab5A gene is  involved in 
the progre s ion of  many types of cancers .  I t  was found that Rab5A acts as an oncogene 
and it has been con-e lated with lung, stomach, and hepatocel lu lar carc inomas (Zhao et a 1 . ,  
20 1 0) .  
2.1.3 JAKISTAT Pathway 
EGFR act ivates Janus k inase ( J A K) .  which is  a fami ly  of intracellular non­
receptor t)Tosme kina etbat transduce cytokine-mediated signals via the JAK-STAT 
pathway. The JAK-STAT pathway is crit ical in nOlmai hematopoiesis ,  survival, 
pro l i feration and oncogenesis (F igure 2 . 1 ) . The J A K  fam i ly of k inases is  involved in  a 
variety of  d isease states. i nc luding inflammatory cond i t ions, hematologic malignancies, 
and solid tumor (Quintas-Cardama & Verstov ek, 20 1 3 ). 
2.1.4 PI3 K1 A KT Pathway 
Activat ion of the EGF receptor resu l ts 1 11 autophosphorylat i ull of kc: tyros ine 
res idues .  As show\1 in F igure 2 . 1 EGFR activates phosphat idy l inositol 3-k inasc ( PI 3 K )  
that phosphorylatcs pi1ospha l luyl inosl tol 4 .5-biphosphatc to (arm phospha(idyl in()� i to l  
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3 ,4,5-tripho phate, which then acti vate Akt by binding at  i ts plcckstrin homology (PH) 
domai n ( yatl et a 1 . , 2006) 
AKT J k inase is n erine/threon ine kinase known to increase cell survival by 
regulat ion of the intr insic pathway for apoptosi s .  A l terat ion in the AKT pathway can lead 
to abnormal cel l s igna l ing. leading to cell prol i ferat ion, di fferentiat ion, urvival and 
migrat i  n. The resul t  or such uncontrol led cel l s ignal ing promotes the acquisit ion of a 
cancerous phenotype. Phosphorylated Akt has several effects, both in the cytoplasm and 
in the nucleus, which include the inhib i t ion of proapoptot ic  factors such as BAD. Akt­
mediated act ivat ion of mammal ian target of rapamycin  (mTOR) is a lso i mportant i n  
s t imulat ing c e l l  pro l i ferat ion ( yati et a 1 . ,  2006). 
2. 1 .5 l.\lA PKIE RK Pathway 
EGFR a l so act i  ates s ignal transduction networks to MAPKIERK pathway, which 
a l lows cel l s  to perceive changes in the extracel l u lar environment and p lays important rol e  
i n  ce l l  mot i l i ty ,  gene expression and cel l cycle progression (Figure 2 . 1 ) . M itogen­
activated prote in  k i nase (MAPK) cascades is among the most thoroughly studied of signal 
tran duction systems and have been shown to part ic ipate in a d iverse array of cel l ular 
programs, inc luding cel l  d i fferent iat ion, ce l l  movement, cel l d iv is ion, and cel l  death 
( Schaeffer & Weber, 1 999). 
I n  mammal ian systems, M A P K  modulate Extracel lu lar s ignal-Regulated K inase 1 
and 2 (ERK L2)  cascade. which regu lates ce l l  growth and d i fferentiat ion and is involved 
in the regulat ion of meiosis and m itosis .  Abcrrant act ivation of the ERK path\vay has been 
sho\\ n to be an essent ia l  Icalurc cOlllmon to many types of human tumors (SmIth 
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& chmid,  2006).  Thus, inhibi t ion of the ERK pathway i s  an  attractIve strategy for cancer 
treatment. 
2 . 1 .6 C O K  Path" ay 
Many of our cel l  can be triggered to d i \  ide upon the proper mutagenic st imulu . 
The ce l l  cyc le must copy the parent cel l ' s  chromosomes and seal them in  a safe daughter 
ce l l  wi th a l l  of the essent ia l  compon nts needed for the daughter cel l to funct ion on i ts 
own. The human cel l  cyc le accompl ishes th is  i n  approximately 24 hours through four 
major pba es :  G 1 ( gap 1 ), ( D  A Syn thes is ) ,  G2 (gap 2) ,  and M ( mitos is) .  Each phase 
se[\ es a pec i fic funct ion to ensure proper cel l  d iv is ion (Wi l l ,  2002) . 









F igure 2 . 3 :  The Cel l  Cycle 
The cel l progresses through i t s  d ivi sion cycle, G 1 ->S->G2->M, in  the presence of 
growth i gna ls  and active CDKJcyc l i n  complexes spec ific for each cel l cyc le .  Stage GO, a 
non-div id ing but functional phase, occurs in  the absence of growth signals (Figure 2 .3 ) .  
F ina l ly .  cyc l i n  degradation i s  i l lustrated by the  S-pha e cyc l inlCdk complex (cyc l in  
E/Cdk2) and the G2 M cyc l in/Cclk comp te :.. (cyc l in  B/Cdc2),  \\ here each must be 
1 4  
synthesIZed and degraded sy temat ical ly for proper ce l l  cycle  progression into the  next 
phase ( \\-' i l L  2002) .  
I n tracel lu lar cyc l i ns and cyc l in  dependcnt k i nase (C DKs) function as  centra l  
regu lator o f  both the cel l  cyc le  and transcript ion. CDK2 activation depend on 
pho'pi1orylat ion by a CDK-activating kina e ( AK) (L iu  & K ipreos, 2000) .  
Accumulat i ng evidence that inh ib i t ing the  act iv i ty of CDKs may be an effect ive 
therapy in  cancer , including brea t cancer. led to the development of sma l l  molecules that 
spec I fica l ly target subgroups of CDKs, including C DK4 and C DK6, the k inases act ivated 
by cycl l l1 D ( Sutherland & Musgrove. 2009) .  
For the past two decades, there have been i ntense studies on the s ignal ing 
pathways i 11 \  oh ed i n  ce l l  growth and pro l i ferat ion. New targets upstream and 
dOWIL tream of  the key pathway are being d iscovered, rev ised and in terl inked with each 
other, enab l ing  extracel l u lar signals to e l ic i t  mul t ip le biological effects .  
2 .2  Phytoch em icals  
Phytochemicals (phyla meamng plant in  Greek) are natura l ly  occuITmg 
b1010gical ly active chemical compounds found in plants .  They have function in  
protec t ing p lants from disease and damage and contribute to the  p lant ' s  color, aroma and 
flavor. S tud ies have shown i ngested phytochemicals show potential  for reducing the risk 
of cancer and card iovascu lar d i sease in humans (Gibson et a I . ,  1 998) .  
Phytochemicals are also avai lab le  i n  supplementary forms, but there is  
i nconc lus ive evidence that  they pro\' ide the �all1C benefi ts as dICtary phytochemical 
( .:vlatha l ,  2000 ) .  As shown in Table 2 . 1 .  there are three major c lasses of  phytochcmicals :  
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1 )  Phenols, inc luding the subc lasses flavol1oids and iso flavones; 2 )  Thiol , includ ing the 
subc lasses indolcs, d i th iol th iones and isoth iocyanates; 3) Terpencs, includ ing the 
subclas:e, carotenolds and l imonoids. With in each subclass are individual 
ph) tochcI11 lca i  (Meagher & Thomson, 1 999). 
2.2. 1 Fu nct ions of Phytochcmicals  
,l any researchers hu\ e focused on phytochemicals for their possible role I II 
prevent ing or treat ing cancer and heart di case (Mathai ,  2000). 
I II cancer. phytochemicals may detox i fy substances that cause cancer. They 
appear to neutra l ize frcc radicals ,  i nhibi t  enzymes that activate carc inogens, and activate 
enzyme that detoxify carcinogens, For example geni te in,  accord ing to data summarized 
by 1 cagher and Thomson ( 1 999) prevents the f0J111at ion of new capi l l aries that are 
needed for tumor growth and metastas is  ( M i l ler, 2002 ) 
2.2 .2  Possible Mechanisms of Action 
C hemoprevent ion of cancer i s  a cancer control  in which the OCCUlTence of this 
d isease i p revented by admin i stration of chemical compounds. They can halt or at least 
retard the development and progression of precancerous cel l s  into mal ignant ones. 
Chemoprevent ive agents are subd iv ided into two main categories b locking agents and 
suppress ing agents,  B lock ing agents prevent carcinogens from reaching the target si tes, 
from undergoing metabo l ic act i\'ation or from subsequently in teracting with cmcial 
cel l u lar  macromolecules.  Suppress i ng agents, on the other hand, inb ib i t  the mal ignant 
t rans f0J111at ion of in i t iated cel ls ,  in  e i ther the promot ion or the progression tage as 
shown in F igure 2.4 ( S urb, 2003) .  
u- Re..t.wa I C 




Carcinogenesis i s  initiated with the transformation of the normal cell into a cancer 
cel l .  The e cel ls undergo tumor promotion into pre-neoplastic cells, which progress to 
neoplastic cells .  Phytochemicals can interfere with different steps of this process. Some 
chemopreventive phytochemicals inhibit metabolic activation of the pro-carcinogens to 
their ultimate electrophil ic species, or their subsequent interaction with DNA. These 
agents therefore block tumor initiation. A lternatively, dietary-blocking agents can 
stimulate the detoxification of carcinogens, leading to their secretion from the body. Other 
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phytochclTI lCa ls  suppress the latcr steps o f  mult i stage carc inogenesis. Some 
phytochemicals  can act as both blocking and suppre srng agents ( Surh. 2003 ) .  
Table  2 . 1 :Commol1 ph) tocbcmlcals, identi ficd by c la  s, sourcc and function 
C I a  � Subclas� PhytochemIcal Plant Source Possible functIon 
Cyal1 ldln.  
Fla\  onolds dclph11l ld 1 1l ,  Bemcs (esp.  b i l bemes and 
. \nthocyan11l s  malvH.hn.  b l uebernes) . -AntIOxIdant. 
t n::d. bluc and na·Ull l ll .  kale.  w i lle, beans. red o May st I m u late 
purplc pelargo1l 1dan. cabbage, eggplant detox IficatIOn 
pI gmen is) peonldl 11 enzymes and 
O hve . onIOns, kale, protect l Iver 
- Flavonols :  lettucc, c herry tornaLO. -Strengt hens 
Quercetl1l. broccol i .  app les, capi I laries. 
kacmpferol yel low/green beans. turnip ' B locks 
greens, endive lea, apple 1 1l nammation. 
juice ' May inhibi t  
o F lavones :  Celery.  o l ives tumor fonnatlOn. 
A n t ho:\an thl ll s  ApIgenin, l u teo l m  
1 P henols (colorles , or 
w h i teto-yel lo\\ oFlavanols:  Pears. red w me, green tea, 
p Igments) Catec h l11, \, h l te W l1le. apple 
eplcatechin 
'May inhIbit  
estrogen-
promoted 
o l soflavone : Soybeans. lenti ls ,  cancers 
(phy toestrogen ) dry peas, soy products o Lower serum 
Dladzei n ,  genIstein cholesterol 
o May l imIt  
effects of 
menopause 
o Lignans: F laxseed, l i nseed, wheat, oAntioxldant 
(phytoe trogens) barlcy. beans, peas, whole o ;v1.ay protect 
Coumestrol,enterola grams. fungI,  tea, pumpkm agaInst cancers. 
ctone, seed , sesame seeds, oAnti, iral, 
enterodlOl ,  peanut , cranberries antlbactenal, 
zearalenone, ant I funga l .  
zeara lenol, o May lower 
sesamlll. serum cholesterol 
I sesamoJinol 
H ydroxyc 11lnam lc B l ueberncs, cherri es, 
aC Id;:,: pears, apples, 
Ca lTelc. feru l lc. oranges. v. hlte  potatoes, 
I chlorogenlc.  grape frU It,  co lTee beans Phenolic aml neochiorogeil lc 
I aC Ids 
Hyuroxyben/oic RasphelTles. stmwbcITies. 
acids:  gn:L'll and black grape 
l; l I aglc, g.a l l lc aCid, �c , L -- -- - -� 
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LentJ ls, black-eyed peas, 
Polyphenols Catechm,  l ight and dark grapes, 
(tannms) cplcateehl l1 red and \\ hlte wme, apple 
polymers JUIce 
- Antioxidant 
Carrots, cantaloupe, - M ay protect 
A Ipha carotene, buttcmut squash, against heart 
beta carotene pUl11pkm , SV\ eet potatoes dIsease and 
stroke. 
-Antioxidant. 
Lycopcne • May protect 
Carotenoid ( rell-orange Tomatoes, red grapefruit, agamst cancers of 
pigment ) guava, d ri ed apricots, the cervix.  
watennelon stomach, b l adder. 
colon and p rostate 
2.Tcrpene· ·Antioxidant. 
L utel l1 ,  zeaxanthm Dark green leafy • May protect 
( xanthophyl ls)  vegetables, broccol i ,  k iwi  agamst heart 
dIsease and 
stroke . 
• May b l ock 
action of 
L l ll1onoids Limonene. sobrerol, Ci tnls fru i t ,  c i trus o i l ,  carcinogens. 
(monolerpene ) peri l l y l  a lcohol caraway seeds • May i n h ibit 
honnone-related 
cancers 
• May block 
carcinogens and 
suppress 
Dial lyl disu lfide. Gar l ic ,  onions, leeks, carclOogenic 
D l a l l y l s u l fides S-a l l )  I cysteine, shal lots, chIves, broccol i ,  changes i n  cel ls .  
3 .Thiols  a l l t c i n  cabbage, cau l i flower, • May st imulate 
B russels sprouts,  mustard, detox i ficat ion 
horseradish, watercress enzymes. 
r ndole- 3 -carbidol • May protect 
I ndole ( I3 C )  against breast 
cancer. 
I soth IOcyanate S u l foraphane • May protect 
against colon 
cancer 
• Stimu late 
detoxi fication 
enzymes 
- Protect against 
ci garette smoke 
2.2.3 P hytochemical  Researc h  
Srudie!'> have looked a t  the re lat ionship between cancer risk and phytochemicals  It 
has been suggested that people can reduce their r isk of cancer s igni ficantly by eating 
more herbs that conta in  beneficia l  phytochcmicals .  Spcc i lic studies shovv that 
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phytochemicals from the herb cal led OriganuJII mojorana exhibi ts anticancer act iv i ty by 
promoting ce l l  cycle an-cst and apopto is 111 brt;ast cancer cel l  l ine (AI  Dhaheri et aL 
20 I 3 ) . Other studic� have hov;n that 'a lrron a lso has a s ignificant chemopreventive 
effect  against li\ er cancer through inhibit ion of cel l pro l i ferat ion and induct ion of 
apopto i (Amin  et a I . ,  20 1 1 ) .  
2 .2 ,4 Phytoc hemica l  Action on Cancer Path ways 
� lan) in1race l l u lar s igna l - transduction patlwvays converge with the activat ion of 
the transcript ion fac tors NF-KB and AP l ,  which act  independently or coordinately to 
regulate target-gene expression. The chemopreventive phytochemicals that are derived 
from the diet have been shown to suppress const i tu t ive NF-KB activation in mal ignant 
ce l l s  (Stu-h, 2003 ) .  
A P  1 i s  another transcription factor that regu lates expressIOn of genes that are 
i n\'oh ed i n  cel l u lar adaptation, d i fferent iation and pro l i ferat ion.  Functional act ivation of 
A P  1 1 associated with mal ignant transfonnation as wel l  as tumor promotion.  AP I 
consi t s  of  e ither homo- or heterodimers between members of  the ruN and FOS fam i l ies, 
which i nteract via a leucine-zipper domain .  The M APK-signal ing cascade also regulates 
thi transcription factor. Many of the molecular a l terat ions that are associated wi th 
carcinogenesis occur in  cel l -s ignal i ng .  One of the central components of the intracel l u lar 
s ignal i ng network that maintains homeostas i s  is the fami ly of prol ine-di rected 
serine, threoni ne k inases the mitogen-act ivated protein k inascs ( YlAPK) as sbown in  
Figure 2 . 5  ( S urh, 2003) .  Abnormal or  improper acti \ 'ation or s i lencing of the  MAPK 
pathway or i t s  downstream transcription factors can rC5u l l  in  uncontro l led cel l growth, 
leading to mal ignant tran<;format ioll . 
20 
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Figure 2 . 5 :  Effect of phytochemicals on activation of NF-KB and API  
On the other hand, some phytochemicals can 'switch on' or  ' turn off ' the 
pecific signal ing molecules, depending on the nature of the signaling cascade they 
target, preventing abnormal cell  prol iferation and growth(Surh, 2003). 
To investigate how phytocbemicals can be used to treat cancer, in silica 
molecular docking has been adopted in several studies. Phytochemical and target protein 
structures are col lected and molecular docking algorithms are employed to investigate 
whether a phytochemical is likely to bind to a protein and if yes, the binding site and 
specific protein-chemical interactions that faci l itate the binding. 
2.3 In Silico Virtual Screening for Drug Discovery 
Virtual screening is a central technique in drug discovery today. Many molecules 
can be tested in silica with the aim of selecting the most promising ones and testing them 
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expenmental ly which al low researchers to re fine their experimental programs t o  reduce 
costs and 1I1.crease research effic iency (Tri i lowatl & Mal let, 20 1 2) .  Moreover, 
computational tcchn lque� ha vc been used in drug d isco\ ery to search l ibraries of small  
molecu les in order to Ident i tY tho e structme , which are most l i kely to bind to a drug 
target, by \ i rtual screen ing. (Tris i lowati & Mal let, 20 1 2 ) 
2 .3 . 1  Adva ntages of III Silico Stud) 
Computer model i ng i an essent ia l  component 1 11 modem pre-e lmical  drug 
di CO\ CI) and de\ c lopment. Instead of test ing each compound in a l arge compound l ibrary 
cxperimcnta l l) by us ing h igh-throughput screen ing ( HTS), virtual screening tools can be 
used to rank molecules on their probab i l i ty of b inding to the target. This l eads to 
considerable sa\ i ngs in personnel and material costs as only a smal l  number of molecules 
of the complete l ibrary need to be tested experimenta l ly ( Tris i lowati & Mal let, 20 1 2) .  
The reason of  choosing computational study i s  that tradi t ional laboratory-based 
cancer research involves expensive trial and error experimental strategies appl ied to 
humans, animals ,  and their t i ssues. H owever in silica experiments provides a novel 
approach to gui de the earl) stages of hypothes i s  development and experimental design 
that has the potent ia l  to create subsequent effic iencies and cost savings in the laboratory. 
This  computational approach is ad,'antageous because it al l ows vast numbers of 
experiments to be calTied out  that  are eas i ly observed at any desired level of deta i l  and can 
be repeated and control led at w i l l  (Tris i lowati & Mal let ,  20 1 2) .  
S uch studies i nvolving i n  pirro and il7 1';\,() animal expcriments invo l \'c hypothes i s  
generat ion and test ing to  detenn l l1e \\ hethcr tL1I1hcr tr ials arc vvamll1ted and arc extremely 
costly both in terms of researcher..; t i m e  and the assocIakd linancla l  Investment .  Costs, 
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such as l aboratory ctup equipment and space, t ime spent by  academics lrain l l1g others. 
and thc t Ime,  equipmcnt, and materia ls  costs 1m olved in repetit ive, hands-on experimental 
\.\ ork, a l l  contributc to the c:\.pe nse of laboratory-ba�cd experimental rescarch (Tri s i lowati 
&. .i\fa l l et ,  20 1 2 ) .  
Moreover, in \ 'itra and  il7 vi\'o model use actual bio logical materia ls  and/or actual 
an imal.  to invc,t igatc h) pOlhe es and predict effect iveness of treatment strategies. 1n 
silica models use spec i fical l)  de igned computer programs to mimic  these " real" 
e .... perimcntal em i ronments and to conduct computational experiments . 
2,4 Molecu lar  Docking 
Molecular docking is  a key tool in structural molecu lar b io logy and computer­
ass i sted drug des ign (Monis and L im-Wi lby, 2008) .  I n  combination with v i rtual  
screen ing,  molecular docking has become a standard tool i n  computat ional biology. This 
technique i s  \v idely appl ied [or studyi ng the in teract IOn between l i gands and prote ins for 
potent ia l  b i t  compounds for protein targets. Tradi t ional ly,  the dock ing process was 
thought of in temlS of "Iock-and-key". L igands, i nc luding smal l molecules,  DNA/RNA, 
l lp i ds.  and even other proteins  sen e as the "key", wh i le the receptor sen'es as the " lock" . 
Once a compound i s  docked, i t  is thcn scored us ing mathematical models by 
est i mat ing the b inding affin i ty of the l i gand-receptor complex. D i fferen t  protocols  for 
dock ing are attempted before determin i ng  the correct set of parameters to be used for 
dockmg.  
2.4. 1 Advantage of Molec u l a r  Docking 
Molecu lar dock ing attempts to predIct  b l 1lLi l ng l Jl leraction� and orientat ions .  I t  
i s  w lddy used i n  rat iona l drug des ign and structu rl' ba-;ed drug design proce'ises. A nother 
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good rea o n  why many researchers arc mov l l1g towards docking methods i n  their 
research i because i t  i s  o ften d i fficu l t  to di scern the precise atomic  level 
i n teract ions through trad i t ional experimenta l \\ ays. 
The abi l ity of the computer to s imulate the interact ions in atomic detai ls and with 
the I l1crea mg PO\\ cr of  computers, in silica methods arc able to provide the answer to 
se\ cra l  d i fficu l t  research problems. 
Evaluat ion of the docked and scored complexes leads to the select ion of a short 
l i ' t  of compounds that can be moved to the laboratory for in vitro, ex I'ivo, and in vivo 
testing .  TIm . molecu lar docking p lays an important ro le i n  the rat ional design of drugs. 
2 .4.2 Class ificat ion of Docking Progra ms 
The dock ing process inv o lves exp l ic i t ly  predict ing the b inding geometry and 
interact ions between l igand and receptor and est imat ing the b inding affinity of the 
l igand-receptor complex ( scoring). F lexible docking programs can be broadly d i \' ided 
i nto two c lasses ba ed on the conformational searching a lgori thms appl ied, includ ing 
v tem methods l ike i ncremental construct ion, confom1at ional search and 
tochast ic random methods sLlch as Monte Carlo, genetic a lgorithms ( Kontoyianni et a 1 . .  
200�) . Widely u ed docking programs, such as FlexX ( Kramer et a I . ,  1 999) belong to the 
fir t cla 5: whi l e  GOLD ( Verdonk et a I . ,  2003 ) and AutoDock ( Goodsel l et a l . ,  1 996) 
belong to the second one. G L I DE ( Frie ncr et a l . .  2004) program uses a combination of 
confom1at ional searching and stochast ic  a lgori thms. The two major components of any 
dock ing tool arc the docking a lgorithm and the scoring fUIlc t ion .  
In  th is  thcsi" the GOLD docking tools \\ ere used. GOLD is  a docking program 
pro\ ided by the Cambridge Crysta l lographic Data Centre (CeDC) .  It lISC · a genet ic 
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carch a lg  rithm (GA) based on Mcnde l ian genet ics for finding poss ible binding modes 
and to c"\.plorc the ful l  range of l igand confonnational flexib i l i ty with part ia l  flex ib ibty of 
thc prote in .  and at is f ic the fundamental requirement that the l i gand must d isplace 
loosel) bound watcr on bind ing (Jones et a l . .  1 997) .  
GOLD al low \\ atcr molecules to be switched 'on' and 'off,  d isplaced and to be 
rotated around their thrce principal  axes to opt imize hydrogen bonding dur ing dock ing. I t  
can automat ica l ly  detennine whether a \\ ater molecu le should  b e  bound or displaced by 
the l i gand during dock ing. The orientation of the ,"vater hydrogen atoms can a lso be 
opt im ized by GOLD during docking. GOLD explores the confoIDlational space of a 
l igand us ing genetic search algorithms in  combi nation with various scoring functions. 
2A.3 Genetic Algorit h m  
Predict ing which in teract ions a l igand makes with a protein in  pose prediction 
step depends on the dock ing software used. The most popular options inc lude genetic 
a lgori thms. Genetic a lgorithm is  implemented in the wide ly used GOLD ( Genetic 
Opt imizat ion for L igand Dock ing) docking too l .  
Genetic algorithms are appl ied to  finding possible confonncrs. A conformer is  
encoded a a s tr ing of  values ( torsion angles)  cal led chromosome. Detai ls  of d ifferent 
implementations d i ffer but the general idea is  the same (T i ikkainen, 20 1 0) .  
The process starts w i th a number of random confonners, which are encoded i n  
chromosomes. Each confoIDler ( set of tors ion angles) is  evaluated with a fi tness function, 
\\'hich  quant i fies the qual i ty of the olut ian. The popUlat ion or  chromosomcs is then 
sLlbJect�d to a modi ficat ion step w here they can go through cross-O\ er ( two 
chromosomes swapping picces) or POl l1t muta t ions (random change in one or 1110rc of 
2 5  
propcrt l cs of  the chromosome) .  A ftcnvards the result ing chromosomes arc evaluated and 
the top scoring ind l \  idual arc taken for anothL:r round of election. The proce s i s  
teml in<ltcd a fter a g i\  en  number of loop (Ti i kkaincn, 20 1 0) .  
2AA Scori ng Fu nctions 
[0 quickly estimate the b inding free energy of a given docking pose, 
mathematical functions, commonly kno\\ n as scoring funct ions, are used. These can be 
categoriLed into three main groups: knowledge-based, empirical and mo lecular 
mechanics force field scoring functions ( Khan ct a1 . , 20 1 4) .  
I n  order to sa\ e computat ional t ime  scoring functions only consider the d irect 
contact i nteract ion between the l i gand and the protein,  thus disregarding any long-range 
i nteract ions.  Scoring est imates tbe chemical interactions such as binding strength and 
energy state between the l igand and prote in  to assist in ranking the efficacy of the 
compound being scored. The score gives a guide as to how good the pose is; tbe h igher 
the score. the better the docking resul t  is  l i kely to be. Ranking of docking is divided into 
in terna l  and externa l  ranking ( Khan et a ! . .  20 1 4) .  
I nternal rank i ng, a s  a molecule i s  docked t o  a s i te. several d i fferent poses are 
generated. Each of the poses i s  eva luated and cored us ing the selected scoring functIOn. 
Thus, an in temal rank ing between all po e of tbe molecule in the i te is  created. The top 
ranked pose is the pose that the docking program suggests is the lowest energy "the best" 
po c of the molecu le  in that speci fi c  s i te .  In thcory ,  th is  would be the same pose the 
molecu le  woul d  d isp lay in a c rystal stnlcturc of the complex .  However, external rank ing, 
j ust as the d i fferent poses of one molecule in the "ame s i te are eva l uated with .;;conng 
functions, the h ighest scores obta l l1cd I'or  each ll1okc u1c  can then be compared to create 
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an external ranking. thu  determin ing \ \  h lch molecule is the  better b inder CKllan e t  a 1 . .  
20 1 4) .  
2 .5 l\l olecu la l' Dyn a m i c  S i m u l ation 
�101ccu lar docking is per[onncd as an ini t ta l  step fol lowed by molecular 
dynamic� ( M D) s imulal ions.  A l though molecular docking is a fast and efficient way to 
qUIck l y  ��tl mate the binding mode of a l igand in to a binding pocket, i t  i s  not the most 
accurate method for determin ing interaction energies .  Molecu lar dock ing programs 
calcu late their scores from a s ingle l igand pose fitted into a snapshot of the protein .  
A l though th i  method aves computational t ime, i t  can a l so be a source of  inaccuracy. I n  
molecular dynamics (MD)  s imulat ions the system i s  s imulated under thermal 
fluctuat ions .  such as it i s  in rea l  bio logical systems ( Khan et a 1 . .  20 1 4) .  
M olecular dynamics i s  currently the  most popular s imulation approach. I t  carries 
out i mulat ions on the computer that arc di fficul t  or impossible in the laboratory l ike 
working at  extremes of  temperature or pressure. This technique a l lows the study of  
biological and chemical  systems a t  the  atomist ic level on t imescales from femtoseconds 
to m i l l i  econds. It complements experiment whi l e  a lso offering a way to fol low processes 
d ifficul t  to d i scern with experimental techn iques. Numerou software packages exist for 
conduct ing M D  s imulations of which one of the widely used one is AMBER 
(Sa lomon-Ferrer et a l . ,  20 1 3) .  
AMBER inc ludes the col lection of  numerous programs that work together to  
setup, perfonn, and analyze M D  s imulat ions. from the preparat ion of the necessary input 
fi les, to the anal}sis of the resul ts .  The name AMBER also refers to a series or c lassical 
molecu lar l1lechanic� force fie lds, primari ly deSIgned for the s imulation 0 1' biol11olcculcs. 
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This I I1c ludes thc amino acid and nucle Ic acid parameter sets, tenned, for example,  f�4, 
ff99 B, and [n 2 B; carbohydrates temled G lycam; phospho l ipids tem1ed Lipid: nucleic 
a ids; and genera l organic molecule tcnncd GAFF ( a lomon-Fener et a1 . ,  20 1 3) .  
Al l  atoms arc treated as spheres \>.,' i th attributcs such as mass, part ia l  charges and 
van der \\�aa l .  radI I  a l lowing the  calculat ion of the  potential  energy at each configuratIOn. 
In rD, atoms arc moved according to Newton ' s  laws of motion and the force of each 
atom i at t ime r i calcu lated [rom the gradient (\7) of tbe force field potential energy 
funct IOn.  Thc accelerat ion of each atom is calculated us ing Newton ' s  second law and the 
"eloci t) and t ime can be approximated from it using a truncated Taylor expansion ( Khan 
ct a 1 . ,  20 1 4) .  
a · ( t) = � = - 2..\7i U 1 
m l  1H i  
p o t  
2.5. 1 Molec u l a r  Dyn a m i c  S i m u lat ion Steps 
The steps for a typical MD s imu lat ion of a protein ,  starts from a structure fi le  
obtained from the  PDB before proceeding through min imizat ion, equ i l ibrat ion, and 
product ion s imulat ions to obtain meaningfu l  resul ts .  The goal of the equ i l ibrat ion stage 
of an MD s imulat ion is  to separate the trajectory in to two port ions:  one contain ing n011 -
equ i l i br ium fluctuations due to the i n i tia l  non equi l ibrium structure, and one which is  free 
of those fluctuations 
Logica l ly ,  a robust equ i l ibration method has important characteristics. M ethod 
houl d  prO\ ide an equ i l ibrat ion t ime that is i ndependent of the duration of the s imulation 
but solely on the phyS1CS of the system. I n terest ingly,  equ i l ibrat ion procedures for 
structural studie' of proteins hm e not cbanged s ign i ficantly as computational resources 
have increased. \Vhen the RMSD rcachc'i a p la tcau valuc.  the system has reached a ba� 1 11 
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i n  the  potenLJal  energy <;urface. Th i  energetic basin i s  as umed to  correspond \\ i th  the 
equ i l ibrium pha -e space, and the system I deemed suitable for the product ion stage of 
molecular dynamic s imulation (Vv al ton & VanVl iet, 2006). 
2.6 To x ic i t} Data 
III sillCO techniques appear to be the best choice to screen compounds with 
unkno\\ n to:>' IC  potent ia l .  r IO\\ ever, in \'ilico model ing of toxic i ty data is extremely 
chal lenging due to the complexi ty and considerab le variabi l i ty of the data i tself  
The  major cha l lenge in toxic i ty model ing i s  that a l l  molecules are toxic at some l evel .  I t  
i therefore necessary that an in silica method can predict both the type of tox ic i ty, as 
wel l  a � the le\  e l  of tox ic i ty of a compound. Since there are numerous different ways in 
which toxic ity can arise, the predict ion of the absolute toxic potent ia l  of a compound, 
e ither from animal models ,  or via in vitro or in silica methods, is extremely chal lenging 
(Gleeson et a l . .  20 1 2 ) .  
In  add I tion,  tbc  level of  tox ic i ty for a given toxici ty mechani sm may a l so depend on  the 
l eve l  and d is tlibut ion of drug in the body (ADME processes), mak ing accurate toxic i ty 
predict ion even more d i fficul t .  The Osiris Property Explorer was used in th is  study 
( http: W\\'\\ .openmolecu les .org/propertycxplorer/applet .html) .  The OS IR lS  Property 
Explorer can be II ed to draw chemical structures and calculate on-the-fly various drug­
re levant propcI1ies (cLogP, solub i l i ty ,  Molecular Weight,  Toxic i ty Risk Assessment 
( indud ing mutagenic i ty .  tumorogenic i ty, i rr i tant and reproductive effect, overal l  Drug­
Score, ctc) whencver a structure is \ a l id to ensure that the drug is suffic icnt to ach ievc 
proof of concept. efficacy and safety' in c l in Ica l  tria l s .  
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Predict ion re u l ts  are , a lued and color-coded. Propert ies v- i th h igh risks of unde ired 
effect" I l kc mutagen ic i ty or a poor mtest inal ab orpt lon arc shown in red whereas a green 
color indicates drug- l i ke beba, ior. 
2.7 III Si/ico C a n ce r  Resea rch 
Virtual 'crccning has been u ed to invest igate anti -breast cancer activity of lov­
molecular \\ eIght compounds presL;l1t in \\  i Id mushroom (Goodsel l  et aI . ,  1 996). This  
stud) con fi nned that c i l1 l1amic ac id  derivat ives e teri fied wi th quin ic acid caused 
sign ificant i nh ibi t ion of the d ifferent protem involved in overproduction of estrone and 
estradio l .  
Another study created a flavonoid compound database that  is found in fi"ui ts to 
gam fmiher understanding of  the ant icancer and therapeut ic effects exerted by these 
phytochemical. .  Computat ional methods were used to select chemicals that target a 
part icu lar protein  or enzyme and to detemline potent ia l  prote in targets for wel l 
characterized a wel l a novel phytochemicals .  They found that isorhamnet in an 0-
111eth) lated flavonol in  herbal mcdic ina l  plants could inhibi t  the k inase activ i ty of  M E K  I 
or P I3 -K and thc i n1 1 ib i t ion was due to i sorhamnet in ' s  d irect binding with these k inases 
(Chen et  a l . ,  20 1 2 ) .  
111 silica dock ing techn iques are being used to  invest igate the  complementarity at 
the molccular Ic,'e l  of a l i gand and a protein target .  I n  a study, n ine l i gands, which have 
been isolated and ident ified from the cthanol ic  extract of the fruits of CuclImi'l 'rigol1l1s 
Roxb, and the standard hepatoprotecti\ e agent i lymarin, were docked with two no\ c l  
hepatocarc inoma rcceptors, I i epat i t is  B X and I Iemc Oxygenase I (Ciopa lakrishnan e t  aL 
20 1 5 ) ,  Out o f  the n ine ph; tuchctll lca l  consti tuents iso lated and idcnt l ficd from the 
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cthanol l c  extract of  the fru i ts of Cuclimis mgolll l'i ,  demeclocycl ine bad the best fitness 
s ore compared with the standard drug, s i l:Yl1lari n. This  suggests that demeclocyc l ine 
could be an cfl'(:cti\  e potential  inh ibi tor against Hepat i t is  B X receptor and can be 
c\ a Juatcd as hcpatoprotcctive drug molecule L ls ing molecular docking studies. These 
e ffcct l \ c propert ies may be due to the presence of carbonyl and alcohol ic-OH functIOnal 
groups present in the I igand molecule .  (Gopalakrishnan ct aL  20 1 5) .  
Among other proteins, leucine-rich alpha-2-glycoprotein ( L RG 1 )  plays an 
important role i n  the  creation of  bad blood vessels .  So, targeting thi  protein may be 
e ffect l \  e I II the treatment of  cancer. A recent in  silica s tudy done by Das  and col leagues 
used the phytochemicals beta-carotene. anlhocyani lls, genistein,  e largic acid, l imonene, 
a l l ic in .  curcLlmin,  which were docked with th is  prote in .  It was ident ified that a l l  these 
phytochemicals ha c good binding affin i ty and Ki value with a h igh H -bond energy. 
Curcum i n, genestein and carotinoid showed a high docked energy and intennolccu lar 
energy. The H -bond shows a lrong interact ion with phytochemicals as a l l  were found 
wi th in  3 A ( Das & Jagadeb, 20 1 5 ) .  
Developing molecu lar drug candidates against a g Iven d isease needs proper 
understanding of the metabol ic pathways. Therefore, identificat ion and development of  
potent ia l  l igands or phytochemical spec ifica l ly for a protein target fom1s thc primary goal 
in drug d iscovery process. Most of these studies are at a sma l l  sca le using a few 
chemicals and a few proteins .  Tn th is  project. se\ eral phytochemicals and protein  targets 
were stud ied in an in silica molecular docking and molecular dynamics study and 
AD�'l ET propert ies vvere also predicted for these compounds. 
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Chapter 3 :  Methodology 
Computational techniques provide e fficient and inexpensive tool to gain further 
und�rsLanding of thc anticanccr and therapeutic effects of phytochemicals .  This  chapter 
descnbes the main steps im 01\ cd start ing [rom obta in ing and preparing l igands and 
target proteins.  Molecular docking \Va done using the GOLD package to find the best­
docked pose. lo lccu lar dynamics s imulat ions using AMBER was perfom1ed to tudy the 
stabi l i ty of  the docked pose and fina l ly to'( ic i ty testing was undertaken us ing the Osiris 
Property Explorer to ident ify any s ide effect  of using these l i gands as drugs. 
3,1 Obta in ing  a n d  Prepa rat ion of Tal'get P roteins 
Protein Data Bank (PDB) ( see F igure 3 . 1 )  i s  a structural database that contains 
i nfom1at ion about experimental ly detcm1ined structures of protei ns and other 
macromolecules .  Structures of the seven proteins ident i fied as targets in cancer pathways 
were obtained from the PDB.  This inc l uded Akt mur i ne thymoma vira l  oncogene 
homolog 1 (AKT 1 ), Cyel i n  Dependcnt K inase 2 (CDK2), Epidermal growth factor 
receptor (EGFR), Extracel lu lar  regulated 2 ( ERK2),  Janus Kinase 1 (JAK l ), M itogen 
Act ivated protein k inase k inase 1 (MAPKK 1 )  and Ras-related protein ( RabSA). 
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Crystal structure of Akt-l -mhlbltor complexes 3 M V H  
Figure 3 . 1 :  Protein Data Bank (PDB) howlllg the crystal structure of  AKT 1 
H igh-re olution tructures of the 7 proteins from humans (Homo sapiens) were 
elected with a re olution les than 2 .5  A. The POB 1D and the related X-ray data are 
bown in Table 3 . 1 .  
N o  P rote i n  name POB 1 0  Resol ution (A) 
1 AKT l  3 MVH 2 0 1 
2 CDK2 4ACM 1 .63 
3 EGFR 3W2S 1 .9 
4 ERK2 20JG 2 
5 JAK I  4EHZ 2 . 1 7  
6 MAPKK I 4AN3 2. 1 
7 Rab5A I N6H 1 . 5 
Table  3 . 1 :  L ist of protein structures obtained from PDB 
After downloading appropriate protein structures from the PDB, for docking, one 
protein chain from each PDB file was used. Each file was processed to remove metadata 
information l ike HEADER, TITLE and AUTHOR, SITE records, etc .  as shown in Figure 
3 .2 .  All  l ines that do not begin with ATOM keyword, which represents the coordinates of 
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the atol11. in  the stnlcture, In rDS fi les were removed keeping only the protem chain that 
\.va necessaI)'. 
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Figure 3 . 2 :  A KT I  PDB fi le wi th a l l  the records shown 
Figure 3 .2 shows the coordinates of the atoms that are part of the protein. Some of 
the header records are a l so shown. A TOM records describe the protein atoms. In  th is  
example the ti rst residue of peptide cham A .  i s  a val i ne res idue with a res idue number 
1 45 .  The second column represents a nll1n ing counter for atoms in the rOB fi le  and the 
th ird column represents the atom ty pe in the res idue. The first three floating-po int 
number� arc the x .  y and '/ coorti l l1L1 tl:s o f  the atom and the uni t  is Angstroms (A) .  The 
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next three columns are the occupancy, temperature factor, and the e lement name, 
respect Ive ly .  
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F igure 3 . 3 :  PDB fi l e  of AKT l ( ID :  3MVH) 
Some of the  PDB fi les obtained had amino ac ids res idues m i  s ing in  the prote in  
stmcturc . F igure 3 . 3  shows the  m iss ing sequence residues of A KT l protein from 1 39-
1 44 and 446-480. 
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I ... �I omplete a tructu re 
Introduction 
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tlW�) � �  .1 1 " -C 1  
Ellhes l ho<",t' .,  pdb-fiJe 
ChooM f. t-.o file chos.n  
Figure 3 .4 :  WHAT IF server 
ThIS may happen when a ide chain or back bone is highly mobile or disordered. 
To fix this problem the mi ing side chains were completed by using 'WHAT IF' 
(http: wift.cmbi .ru.nlt erverslhtmllindex.html) that is capable of bui lding a model of the 
mis ing chains a hown in Figure 3 .4. The final structure of the proteins viewed in 
Vi ual Molecular Dynamics (VMD) tool is shown in Figure 3 .5 .  
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A.AKT l ( 3MVH)  B.  C OK2 (4ACM) 
C . EGFR ( 3 W2S)  O .  E RK2 (20JG) 
E. JAK I (4EHZ) F .  MAPKK l (4A 3)  
F .  MAPKK l (.+AN3 ) 
Figun� J . 5 :  F i xed cha i n  protc in�  v iewed Lls ing VIvI D  
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3 .2  Obtain ing and Preparation o f  Ligands 
Phytochemical tructure were obtained from PubChem 
(http ://pubchem.ncbi .nlm.nih.gov), which i a database of chemical molecules, their 
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Figure 3 .6 :  Chemical structure of alpha carotene from PubChem 
Research over the last decade has shown that several phytochemicals in fruits and 
vegetables could have an effect in cancer. Phytochemical groups such as carotenoids, 
flavonoids and indoles have been chosen in this work based on their anticancer effect. 
Sixty-seven chemicals were obtained in this  project as shown in Table 3.2. Details about 
the plant source and chemical group of each of the phytochemical are provided in this 
table. 
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'\ 0. ( h e m i c a l  'Iolecular ,\ 1 '\ P u bC h c m  P l a n t  n a m e  C h e m ical C r o u p  
'\ a me F o r m u l a  ( g  111 ( 1 )  ID 
Aplgentn C I ,H ,OOS 270.2 5280443 parsley, celery and chamomile flavone 
2 Alpha Carotene C"of l 'b 536.8 4369 1 8  Pumpl.. ln .  arrots and Broccoli Carotenoid, 
3 Beta Sitosterol C29H,oO 4 1 4. 7  222284 Com, soybean and Nuts Phytosterols 
.:I Hctul i n l c  ACid C301 lJ,O, 456 7 6497 1 White birch trce Triterpene 
5 Boswellic Acid C,oH4S03 456.7 1 68928 Gum resl11 Tnterpene 
6 anthuxunthl11 C4oH5201 564.8 5 2 8 1 '227 CalTots, pumpklnsand sweet potaloes terpenoids 
7 Capsaicin C lsHl,1 OJ 305 4 1 548943 Chil l i  pepper Capsalcinoid 
8 Camosol Clof [260J 3304 2579 Rosemary Phenolic Dlterpene 
9 Chi orogenic Acid C16H 180� 354.3 1 794427 Coffee bean, bamboo and potatoes Hydroxycinnamic acids 
1 0  CI) ptoxanthl ll C4oH5bO 552.8 528 1 235 C l tru . fruit, mangos and papaya Carotenolds 
1 1 Curcumin C21 Hl00b 368.3 9695 1 6  Turmeric plant Dlarylheptanoid 
1 2  Daidzcl11 C I5H I004 254 2 528 1 708 Kwao Krua and Kudzu Isoflavones 
1 3  Delphinidin CisH I I07 303.2 1 28853 Pomegranates. grape and CranbelTies Anthocyamdin 
1 4  Delta Carotene CJ'lH 56 536.8 528 1 230 Pumpkin, CalTots and Brocco l i  CarotenOid, 
1 5  EGCG C22H I 0 1 1  458.3 65064 W hite tea, green tea catechin 
1 6  Ellaglc ACid C I 4HoOs 302.2 5 2 8 1 855 Raspberries. StrawbelTies, hexahydroxydlphenlc 
Cranberries aCid. 
1 7  3 ,3'- C 1 ,H 14 246.3 307 1 Cruciferous vegetables Indole-3-carbmol 
D l i ndolylmethane 
1 8  Acacetin C I"[ [ l l0, 284.2 5280442 Black locust ( Robll1ia pscudoacacla) O-methylated flavone 
and damlana (Turnera dlffusa) 
1 9  Anacardic Acid CnH 3,,03 348.5 ] 6755 1 Cashew nut ( A nacardium Phenolic l ipidS, 
occidentale) 
20 ChI) Sin C 1 sl i l JO� ::54 :: 528 1 607 PassIOn flowers ( Passiflora caerulea) Flavone 
2 1  Cyallldin C I 5H I I06 287.2 1 2886 1 Red belTies, red cabbage and red anthocyanidin 
ol1lon 
:!2 DIO 'meWl C 6H 20" 300 2 528 1 6 1 2  C.1UL�blan vetch 0-1l1cthylated tla\ one 
23 Emod l l1 C , \ H  �O, 270.:: 3 2 20 Rhubarb. buckthorn and Japan<:se Resin 
knotwecd 
24 131111111 L a nulenl;.' C 1 1 00, � 7 S A  �2kOl) 3 �  (kl1()tilcr;1 ( ,lrbll') l ie .le ld 
ACid 
39 
25 Gamma Carotene C401 156 536.8 528079 1 Pumpkm. Carrots and Broccoli Carotenoids 
26 )"rcmnl C,.,H 'OO6 602 8 5490 84 Garclnla indica po I yl sopren y lated 
benzophenone 
27 Genistein C I 5H IOOS 270.2 528096 1 Dyer's broom and Genista finctoria I oflavones 
28 Gmgcrol C I lH:6O. 2<)4 J 3473 Ginger. chill i  peppers and black ketone. phenol 
pepper 
29 Glycitcin C I61f l Z05 284.2 53 1 7750 Soy O-methylated isoflavone 
30 I sorhamnctlll I"H l 107 3 1 6 .2 528 1 654 Tagl!tl!s fllcida O-methylated flavonol. 
3 1  Myricetin C l sH loO· 3 1 8.2 528 1 672 Bayberry flavonol 
32 Oleanolic ACid C)OH.�O, 4'i6. '  1 0494 O l i ve o t ! .  American pokeweed triterpenOid 
33 Oleocanthal C I7H:oOs 304.3 1 1 6524 1 6  Olive oi l  phenylethanOid 
34 I\�onldlll C I6H "Oo· 30 1 .2 44 1 773 t\lorning glory and peony flo" ers O-methylated 
anthocyanld1l1 
35 Piceatannol C I4H I204 244.2 667639 Norway spruces and Aiphanes stilbenoid 
horrida 
36 Pmore-Inol C:oI In06 3 5 8 .3 2348 1 7  Sesame seed. BraSSlca vegetables and llgnan 
Forsythia suspensa 
37 Pterostilbene C I 6H I603 256.2 528 1 727 B lueberries and grapes stIibenoid 
38 Res \ era tro 1 C 141-1 1 2O, 228.2 445 1 54 Red grapes and Japanese knotweed stilbenOld 
(Polygonllm cusptdalllm) 
39 Shgmasterol C29H.&0 4 1 2.6 5280794 American ginseng, soybean. calabar phytosterol 
bean, and rape seed 
40 Tangeritin C:01-l2007 372.3 68077 Citnls peels O-polymethoxylated 
flavone 
4 1  Theaflavin C19H 2.0 12  564,4 1 1 4777 B lack tea Antioxidant polyphenols 
·n Guggul terone C2 1 H l�02 3 1 2 4 6439929 Guggul plant SterOid 
43 H esperidll1 ClsH3401 5 6 ] 0. 5  1 061 1 Citrus frUIts (oranges. lemons or flavanone glycoside 
pummelo fruits) 
44 l ndicaxanthin C I.I-l 16N20b 308.2 7 1 308222 Beeb. MI/'obil,sjafapa flowers. betaxanthm 
prickly pears and red dragon fnl lt 
45 l sobetanin C2,H26 'lO ll 550.4 6325438 Beetroot and Amaranthlls spp Betacyanin 
46 Kaempferol C I 5 1 1 1006 2 6.:; 5280863 Tea. broccol i .  Delphinium. W i lch- fla\'onol 
hazel and grapefrull .  
47 La n c ires 1110 I C1OI-l2406 360.-1 332427 Sesame seeds and 111 Brassica phenylpropanOids. 
\ <.!gctabl�s 
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48 Lutein 401 1 '601 568 8 5 308J96 p1l1ach. kale and yellow carrots. Xanthophyll 
49 Lutcoltn C I s i l ioOb 286.2 5 280445 Termmalia chebula. rinds, barks, Flavone 
:Iover blossom. and ragweed pollen. 
50 �facrocarpal A 28 1 1"006 472 fi 4544 5 7  Ellcahpllls globllills Lablll Phlorogluc1l101 
Dlaldehyde. D tterpene 
5 1  !l.lataircsinol CloHll06 358.3  1 1 9205 Otl  seeds. whole graIns, vegetables, hgnan 
and fnnts 
52 r-.lyrcl3phcnone B C' I J [�cO . l  482.3 1 83 1 39 Mvrcw IIlllliijlora Phenohc glycoside 
53 'anngentn C I s H I 20S 272.2 932 Grapefruit and tomato flavanone 
54 Pelargon idin C I s l l l 1 0j 2 7 1  2 440832 Red geraniums. bemes and anthocyanldln 
pomegranates 
55 Quercetin C I s H I 007 302 2 5 2 80343 Sophora japonica flavonol 
56 Vulgaxanth1l1 C 1 4 J [  7N)0, 339.3 528 1 2 1 7  Mlrabtlls jalapa and SWISS chard betaxanth1l1 
57 Ursohc ACid CJoH .. OJ 456.7 64945 Mirabilis jalapa lnterpene acid 
58 1 rametenolic Acid C301 14 ' 03 456.7 5684 1 1 32 Tramclcs iaclil1ca Tetracychc 
Tnterpene 
59 Rosmannyl Cc4H,60 U 522.4 1 1 606086 Rosmarinic acid of rosemary, sage, Polyphenol 
Glucoside Jantsh sage, oregano.thyme, and mint 
60 Rublxanthin C4oH56O 5 5 2 8 528 1 252 Rose hips Xanthophyll 
6 1  Rutin C�7 HJoO I6 6 1 0. 5  5280805 Carpobrotus edulisand buckwheat Flavonoid glycoside 
62 cutellarein C i s H I 006 286.2 5 2 8 1 697 SClllel/ana laler/flora Flavone 
63 S,hblDill C2s H:,:;OLO 4824 3 1 5 5 3  M i l k  thistle Flavonoid 
64 SIlyblll B C:, 1 I 2:O 10 482.4 1 548994 M t l k  thistle Flavonoid 
65 Subaphyll ine C I 4 H zoNz03 264.3 528 1 796 Com fiber Alkaloids 
66 Zeaxanthin C401 1 s6O: 56�n:  5280899 Corn, saffron. wollbernes, Xanthophyll 
67 Yakuchlllone C2oH2;OJ 3 1 2.4 1 3 3 1 45 Alpinia oxyphylla jlarylheptanone glucoside 
Table 3 . 2 :  L is t  of phytochem ical used i n  M olecular Docking study 
2 0  structures of the 07 chemicals  wcre obta ined from PubChcm in SDF fonnat .  
Th i s  wali cOll\ crtcc! to �D t(mnal and Its energy \\ dS m i n l tl l lLcc! lls ing PyRx 
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(http ://pyrx.sourceforge.net). Energy mimmization of the l igand tructures is performed 
to prevent atom from being unfavorably close to each other as shown in Figure 3 .7  
Ligand file were then converted to MOL2 format USlllg OpenBabel 
(https ://pypi .python.org/pypi/openbabel) to prepare it for molecular docking as shown III 
Figure 3 . 8 .  
• _ '" 
Figure 3 . 7 :  Preparing Alpha Carotene by minimizing the structure using PyRx 
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Figure 3 . 8 :  Converting sdf format to mo12 using Open Babel 
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3.3 � l olecu lar  Docking of Ta rget Protei n with Liga nds  
Genet ic Opt imization for L igand Dock ing (GOLD) was used to dock the se lected 
l igands to the pr tems in a flex ible manner. Prote ins that \\ ere prepared previous ly were 
loadcd and hydrogcn atoms \\cre added to i t .  B l ind docking was used to detect possible 
b inding s ites and modes of the l igands by scanning the ent ire volume of the protein  
target . For  th i s  a earch space enclosing a sphere of 30 A was used to Co\ er the whole 
protClI1 . The conformat ional space of  a l igand was explored us ing the genetic algorithm.  
1 00 genetic a lgorithm runs were perfomled in each docking experiment in order to 
ensure that mo t h igh a ffin it) binding modes wou ld be explored. 
ChcmPLP coring funct ions was used to  quanti tat ively evaluate the  qua l i ty of the 
docking. The t ime taken to perfoml a docking i s  a balance between speed and 
accuracy, the lower docking the more accurate w i l l  be. The series of steps fol lowed to 
setup a docking run i hown in  F igmc 3 .9 .  
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Figure 3 .9 :  Main steps of GOLD docking. 
3.3. 1 Analysis Methodology 
After the docking run, the best-ranked pose from the 1 00 runs was chosen. The 
best po e was analyzed USlDg LIGPLOT (http://www .ebi .ac.ukJthomton-
srvlsoftware/LIGPLOTI) and VMD (http : //www .ks.uiuc.edulResearchlvmd/). LIGPLOT 
projects the 3D structure to a 2D image where all the interactions between l igand and 
protein could be identified. Thi al lows a closer inspection of the hydrogen bonds and 
hydrophobic interactions.  
3.4 Molecular Dynamics Simulation of Docked Comp lex 
Molecular docking predicts how a small molecule wi l l  bind to a protein but this is 
not easy, and no program can guarantee success. A further enhancement to this approach 
I to measure as accurately as possible the reliabil ity of the dock using molecular 
45 
dynamic:; (M D). MD s l I11U lat ions have to be sufficiently long to draw re l iablc 
conclll Ions .  
1 D  imulat ions were used for ident i fying and confim1ing the binding poses that 
were found from GOLD docking .  AMB · R tool has the abi l i ty to perfonn long and 
accurate 1 D  s imulations. A 1 B E R  MD simu lat ions were used to predict the molecular 
motions of the prote in- l igand complexes. The s imulations were long enough so that 
repre entative conformations cou ld be sampled. 
Th > docked fi les were prepared for MD s imulat ions by plac ing them fi rst in  a 
cubic box fi l l ed with water molecules and sa l t .  ex t ,  energy min imization of the system 
\Va pcrfonned and then s lowly the ystem was heated to room temperature and pressure. 
F ina l ly.  production MD simu lat ions were performed at the des ired temperature and 
pressure 
3A. 1 M i n i m ization Stage 
Before start ing M D  s imu lations, the energy of the structures were minimized. 
1.1 1 I1 imiza tiol1 remove any unfavorable in teract ions that may exist, v.. h ich might otherwise 
lead to unstable s imulat ion.  The parameters used for the energy min imizat ion stage is shown 
in F igure 3 . 1 0 . 
� i n i m i : a t ion to �elix i n i t i a l  bad con tac t s ,  exp l i c i t  solve"t 
&cnt rl 





Figure 3 . 1 0 : i\ I D  s imulat ion Step I :  rn i ll imi....:at iol1 stage 
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As showed in f igure 3 . 1 0 , to run in i t ia l  min imizat ion, min imizat ion was turned 
on us ing the setting imin - I .  M in im izat ion was '\\ i tched from steepest descent to 
conjugate gradient after 1 000 step (ncYl: ) and the total  number of ml l1 imizat ion steps 
was 5000 ( maxcyc ) .  The intennediatc resu l ts was aved every 50 s teps (ntpr) . A 
nonbonded cuto ff of 8 A (cut) "vas used . Water, CA, C, 0, N atoms were restrained 
(restra in  mask) and the force constant [or restra int 'Was 1 0  kealJmollA2 (restra int_wt) .  
Thi ensures that the prote in  heavy atoms do not deviate s igni ficantly from the original 
stmcture. 
304.2 H ea ti n g  the system 
A Cter the system was min imized, the next stage was to a l low the system to heat up to 
n01111a l  temperature of 300 K .  The temperature of the system was raised from 1 0 K to 300 K 
gradua l ly us ing the fol lowing parameters . .  
Ex?] ic it solvent ini 'Cial n�dt:ing tndin 
&cntrl 
imincO, irest ",,0, ntx:l , 
ntpro;:-leeO, nh.x""190e.1 ns t l i m=200aee, 
d -0 . 03 2 ,  n t t = 3 ,  gaflliJld_ln - 5 . 0 ,  ig- - 1 ,  
t1tc-2,  otf-2 , cut-a, ntb- l ,  




TYP, - TE'�?e , ISTEPl -e , ISTi'P2-1 5aaae, 
VALUi' 1 - 1e . e ,  VALUE2-3ee . a ,  
&" t TYPE- EI/D I 
Figure 3 . 1 1 : M D  s imulat ion Step 2 :  Heat ing stage 
The i nput fi le for th i s  pha e is shown in Figure 3 . 1 1 . Min imization was turncd off 
Umin-O) and the in i t ia l  coordinates were read from the inpcrd file by ntx= } wh ich is the 
output fi l e  [rom the pre\ ious stage, i . c .  m in im i/utioll . Fvery 1 000 steps (ntpr) the energy 
reading� were written to the output fi les v-. h l l e  the coordl t1atcs of atoms \\ erc depo' i tcd 
in to the trajec tory ti le c\ ery I OUO step (nt\\ x) .  The tota l  number or M D  s teps 
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pcrformcdwa:> 200,000 (nst l im)  \\ i th a tnne step of 2 fs per step Cdt) .  The heatl I1g was 
tarted at 1 0K ( \ a lue l )  and cont inut;d unt i l  the desi red temperature 300K was reached. 
304.3 E q u i l i b rat ion a n d  p roduct ion p hase 
The final step of the s imulat ion is to run the s imulat ion in "production" phase for 
the desI red t ime length using the same condi tions as equ i l ibrat ion at constant temperature 
and prcssure. \\ IHch c losely matche laboratory condit ions. The parameters used in this 
, tage are hown in Figure 3 , 1 2 . 
Explic.it solvent r!lolecular dyndmics constant presSure ioU 
&cntd 
I 
il'llin-O, irest-l, ntx-S,  
ntpr-leOOO ,  nu;x-UlGOO, n s t l im-Sooeooeo , 
dt--O . OO2 ,  ntt-3, tempi-3oe, 
tempO-JOe , ganrna_lr.:l . a ,  19- - 1 ,  
ntp-l t n t c - 2 ,  ntf-2,  cut·8� 
ntb-2 , iWr'c1p-l , iovtffl-1 J 
Figure 3 , 1 2 :  M D  S imulat ion Step 3 :  Production stage 
E\ ery 1 0,000 s teps energy infom1at ionwas printed to output files (ntpr) and every 
1 0,000 steps the coord inates were \ui tten i nto the trajectory fi le (ntwx) .  Number of M D  
steps i n  production phase t o  b e  perfonned was 50,000,000 steps (nst l irn),  which 
trans late to 1 00 n of M D  imu lation t ime,  
3.5 A D '\ I E  and Toxicity C h a racteristics of Drugs i n  H u ma n s  
One of the  key cha l l enges of dnlg development is  to  predict drug responses Il1 
humans because drug d iscovery is a time-consuming and expensive effort and may resul t  in 
fai lures in c l in ical tria l s .  The last step in th is  project was to predict the ADMfT 
( Absorption. D istribution, �letabol ism. Excretion and Toxic i ty) propert ies or  the 
phytochemicals used in  th i s  study lls i ng ill \'i/lC'o techn iques.  For this the Os i ris Property 
48 
Explorer (htt : www",-,=.ocr-=-=== 
tbe l igand the M ILE repre entation (Canonical SM ILES) of the elected ligands were 
obtained from PubChem. For example tbe Canonical SMILES of hesperidin (CID:  1 062 1 )  is 
howed in Figure 3 . 1 3 . Thi was submitted to the Property Explorer to be evaluated. A 
ummary of the analy i produced i bown in Figure 3 . 1 4 . 
Canonl�1 SMILES 
ee'c CiC O' )OCC2C( qc 02j0C3.cq. 
Figure 3 . 1 3 :Canonical Smile of Hesperidin (CID :  1 062 1 )  from Pubchem 
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Figure 3 . 1 4 : Analy is of the ADMET properties using Osiris Property Explorer 
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Chapter 4: Results 
I n  th is  s tudy, molecular docking and l D  s imulat ion were used to characterize 
the i nteraction of phytochemicals with se\ eraJ target proteins.  
In rder to gel an in  ight i nto the b inding i nteract ions, inteTI110 lecuJar 
i nteract ions l ike hydrogen bonding and hydrophobic in teract ions were analyzed. These 
bond help in dctcml in ing the binding a ffin i ty and drug efficacy. 
I n  GOLD docking, hydrogen bonding and hydrophobic interactions p lay an 
important role in  stab i l iz ing a l i gand energetical ly in  a prote in .  The number of hydrogen 
bond for each chemical and prote in  were calculated for a l l  dock ing runs.  This 
comparison assisted i n  dec id ing which l igand and targets are the most su i table candidates 
for further studies .  
A fter the prote in- l igand complexe were s imulated, it i s  essent ia l  to check that 
s imulat ion ha equ i l ibrated . One useful measure to consider i s  the root mean square 
deviat ion (RMSD) of the protein atoms witb re pect to the in i t ia l  s truc ture. This  shoul d  
nom1al ly  be l ess tban 2 A i nd icat ing that equ i l ibration was successfu l .  Analyzi ng the 
b i nding d istance behveen protein and chemica ls  i s  needed to test whether tbe l igand stays 
t ight ly bound in the active s i te .  These results produce an atomic- level view of tbe protei n  
dynamics through mul t ip le M D  s imulat ions.  The results showed that the architecture of 
the active s i te i s  s tabi l i zed by several  di fferent hydrogen bonds. Furthem10re, the 
pham1acotogical  propert ies and tox ic i ty of the candidate chemicals was predicted in 
silica to avoid any fai lure in  drug design i ng .  
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4.1 Total ='i u m ber of Hydrogen Bond i n  Molec u l a r  Docking 
Molecular docking resu lts of GOLD v. ere analyzed in L lGPLOT and the tota l  
number or  hydrogen bond lI1teract ions was calcu lated. The resul ts arc summarized i n  
Table 4 . 1 .  
o .  C hemieal  :\ a me A K T  BCLl C D K  EGFR E R K  J A K 1  I\l E K 1  R a bSA 
1 Apigenin 0 0 0 0 0 0 0 0 
2 \ lpha Carotene 0 0 0 0 0 0 0 0 
3 Beta Sitosterol 0 0 0 0 0 0 0 0 
4 Bcru l In lc  ""cld 0 0 0 0 0 0 0 0 
5 Boswelhe  ACid 0 0 0 0 0 0 0 0 
6 Canthaxanthin 0 0 0 0 0 0 0 0 
7 Capsaicm 3 3 0 0 0 3 0 3 
8 Carnosol 0 0 0 0 3 0 0 0 
9 Chlorogenic ACid 3 0 5 4 7 5 6 8 
1 0  CryptoxanthIn 0 0 0 0 0 0 0 0 
1 1  Curcumin 0 0 0 3 3 5 0 3 
1 2  Daldzell1 0 0 0 0 0 0 0 0 
1 3  Delphinidin 0 3 0 3 4 0 3 7 
1 4  Delta Carotcne 0 0 0 0 0 0 0 0 
I S  EGCG 4 0 6 3 8 0 4 8 
1 6  El lagic Acid 4 5 3 4 3 4 5 8 
1 7  3 ,3 '- 0 0 0 0 0 0 0 0 
Diindolylmethane 
1 8  Acacetll1 0 0 0 0 0 0 0 0 
1 9  Anaeardic Aeid 0 0 6 0 5 4 3 6 
20 Chrysll1 0 0 0 0 0 () 3 
, -' 
2 1  Cyanld ll1 0 0 0 3 3 3 3 8 
2 2  
2 3  
24 
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49 Lutcol in  0 3 0 0 0 0 0 5 
50 ;., lacrocarpal A 0 0 0 0 4 0 4 6 
5 1  Mataircsinol 0 0 0 3 7 0 0 4 
52 :\lyrciaphcnonc B 0 5 3 8 6 5 4 1 0  
53 anngcnin 0 0 0 0 0 0 0 5 
54 Pclargol1ldin 3 0 0 0 0 0 0 5 
55 Quercetm 3 3 3 0 4 0 4 9 
56 \ ulga\anthin 0 0 3 4 4 0 6 6 
57 Ursolic ACid 0 0 0 0 3 0 0 0 
58 Tramctenol tc  c ld 0 0 0 3 0 0 4 3 
59 Rosmarinyl 5 6 7 6 5 6 6 9 
Glucoside 
60 R ublxanthin 3 0 0 0 0 0 0 0 
6 1  Rutin 7 5 0 3 6 4 4 0 
62 cutel larein 0 0 0 0 3 0 3 0 
63 Si l ibimn 4 0 3 0 5 0 3 7 
64 Si lymann 0 0 3 0 6 0 7 7 
65 Subaphyl l ine 3 0 6 5 4 5 4 5 
66 Zeaxanthin 0 0 0 0 0 0 0 0 
67 Yakuchinone 0 0 3 0 0 0 3 0 
Table 4 . l :Total numbers of hydrogen bonds behveen the protein and the docked l igand 
10lecular docking re u l t s  showed that some chemicals did not interact with any 
of the protein .  Th is is most l i kely due to the s ize of l igand, the shape of thc bind ing s i te, 
the chcmical structure, the polari ty, or un tlworablc  contacts .  As a resul t ,  some chemicals 
d id not f'oDn good interactions \\  i th the protc in� \\ h i le others showed strong I l1 teracl ion 
5 3  
wi th  good number of hydrogen bonds. GOLD docking showed that RabSA ha  the 
h ighest number of interact ing chemIcals out of the 67 chosen . 
4.2 R a b 5A as a P romis ing Ta rget 
Rab5A.  a member of RA oncogene fami ly  was the most sui table candidate 
protein  ba cd on the resul ts  obtained from molecular dock ing resul ts .  
4.2 . 1  Molecular Docking 
In  mokcular docking, u ual ly l igands bind and in teract \;>" i tb the active s i te of a 
prote in .  This act J \ c si te i the bas is  of the lock and key model .  I deal ly candidate dmgs 
mu t b ind strongly with high a ffin i ty and specific ity to the active si te .  
F Igure cf . l  shows a L TGPLOT diagram of GTP bound to Rab5A as evident [rom 
the co-cry stal l i zcd POB structure (PDB 1 0: 1 N6L) (Zhu et a I . ,  2003 ) .  It can be see that 
GTP I l1 teracts \\ ith the same amino acids that interact with the l i gands in this study l ike 
Ser29.  er3cf.  Ser35and Thr5 , ,,,-h ich indicates that  the l igands are docking in the same 
binding s i te .  
t>.101ecular docking resul ts  hawed that  several chemicals could in teract strongly 
with Rab5A (POB I D :  I N6 H )  as shown in F igure 4.2 and summarized in Table 4 .2 .  
B inding s i te amino ac id  res idues were analyzed to  see whether the  chemicals bound to  
the  acti\e s i te. 
Lys 1 65 
Ala.164 
�- c ' � E 
S .. 10 
54 
Figure 4. 1 :  LIGPLOT showing hydrophobic interaction and hydrogen bond of GTP and 
Rab5A ( PDB ID :  I N6L) 
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B .  InteractIOn of chi orogenic aCid wllh Rab5A (PDB I D :  I N6H) 
Se, 5 1  
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Ph,,48 
C. InteractIOn of cyamdm with Rab5A (PDB ID' ] N6H) 
Ser34 .... 
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Ly .. 33 
E.  InteractIOn of el laglc aCid with Rab5A (PDB ID:  1 N6H) 
Ser29 
1 5 {rol. �n49 
Thr52 
F. l nteraction of emodin with Rab5A (PDB I D : 1 N6H) 
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c • .....  
� .) � 
..; %;lU50 3.�.2 
\ 
Ser 51 
G.  Interaction of EGCG with Rab5A (PDB ID' ] N6H) 
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01 Macrocarpal A 
Gly32 
Ser5 1 
H .  Interaction of macrocarpaJ A with Rab5A (PDB ID:  1 N6H) 
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1 .  InteractIOn of myrclaphenone B with Rab5A (PDB ID:  1 N6H) 
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K .  InteractIOn of rosmannyI gluco ide with Rab5A (POB ID :  1 N6H) 
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L. InteractIOn of theaflavin with Rab5A (PDB ID. l N6H) 
60 
Figure 4.2 : L IGPLOT result of Rab5A (ID:  1 N6H) docking interactions with A. anacardic 
acid, B. chlorogenic acid, C. cyanidin, D .delphinidin, E. eUagic acid, F .emodin,G.EGCG, 
H .macrocarpal A 1. myrciaphenone B, 1. quercetin, K. rosmarinyl glucoside, L . theaflavin. 
6 1  
Based on  the  Rab5A structure that was complexed with GTP ( PDB JD: 1 6L) the 
act l \  c site includes the amino acid : er29, Gly32, Ly 33 ,  Ser34, Ser3 5 ,  Thr 52, Gly78, 
A 11 1 33 ,  Asp 1 36,  A la 1 64 and Lys l 65 Consequently, the dock ing resul ts of Rab5A ( lD :  
L >61 1 )  sho\\ ed that I t  shared the same act i \ e s i te  res idues l ike Ser29, Ser34 Thr52 ,  
Asn 1 33 ,  A la l 64 and Lys 1 65 \\ i th several chemicals incl uding anacrdic ac id, cb lorogenic 
acid ,cyanid in ,  dc\phin id in ,  el lagie acid, emodin,  EGCG, macrocarpal A ,  myrciaphenone 
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1 2  
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Phytochemical  Ammo aC Ids \\ I th Amino ac ids WiUl 
H bond tntcraction Hydrophobic I nteraction 
Anacardic  acid Ser29,  Ser34, Ser5 1 ,  Thr52 G lu2 8  A la30, G ly32, Lys33,  G ln49, 
Gly78,  G ln79, Glu80, Arg l l O  
Ch lorogcl1 lc A la30, cr34, Asp 1 36, Ser 1 63 ,  Ser29, GI� 32,  Lys33 ,  Ser3 S ,  Phe45 , 
aCId 1 }s 1 65 Gln49, GluSO, SerS l ,  ThrS2 ,  Asn l 33 ,  
Lys 1 34, Ala 1 64 
Cyanidin Scr29,Ser34, Ser3 5,  G l u47, Ala30, Thr52, Lys33, Gly32 ,  Phe48 
G ln49, SerS 1 
Delphinidin Ser29,  Ser34,  Scr35 ,  G lu47, SerS l ,  A la30, Gly32, Lys33 ,  Phe48 ,  G ln49, 
Lys 1 34 ThrS2 
E l lagic acid Ser29, Lys33 ,  Ser34, Ser3S ,  Ser5 1 A la30, Lys33 ,  Ser34, Gln49, Gly78 
E modl 11 er29, Ser5 1 ,  Thr52, Thr76, Asp7S A la30, Gly32, Phe48, Gln49, Glu50 
EGCG Ser34, Ser35 ,  Ser5 1 ,  Lys 1 34 A la30, G ly32, G ln49, Phe48, G lu50 
Macrocarpal A Ser29, er35 ,  SerS I Ala30, Ser34, G ly32, Gln49, Glu50 
Myrc iaphenone Lys33 ,  Gly32,  Ser34, G ln49, A la30, Va13 1 ,  G lu50, Ser5 1 
B Thr52 Arg8 1 ,  Gln79 
Quercet in  Ser29,  G lu47,  G l n49, Ser5 1 ,  A la30, Lys33,  Ser34, Ser3 5,  Phe48, 
Thr52, Asp75, Thr76 Gly78 
Rosmarinyl  Asn 1 33 ,  Lys 1 34,  Asp 1 36,  Phe45 , Thr 1 03,  Leu 1 37,  Thr l 03 
g l ucoside Lys 1 40, Ser 1 63 ,  Ala 1 64, Lys 1 65 
Theaflavin Ser34, A n 1 33 ,  Asp 1 36, Lys 1 40, A la30, G ly32, Lys33 ,  Ser35 ,  Pbe45, 
Lys 1 65 
G l u47, G ln49, G l u50, Ser5 l ,  Leu 1 37, 
Ala 1 64 
Table  4 .2 :  Amino ac ids of  Rab5A in teract i ng with the l igand based on hydrogen bonds 
and hydrophobic in teraction 
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4.2.2 Molecular  Dynamic i m u lation 
The MD technique ha been as es ed as a rel iable tool to refine experimental 
tructure Thu , MD imulation were performed for c losely studying the interactions 
obtained from docking. MD imulation re ult howed that only four phytochemicals -
EGCG. el lagic acid, macrocarpal A and quercetin - bound strongly to Rab5A. The active 
lte of the Rab5A-GTP complex (PDB I D :  1 6L) visualized in 3 D  using VMD is shown 
in Figure 4 .3 .  
Figure 4 . 3 :  GTP bound to  the active site of Rab5A showing the hydrogen bonds 
with several amino acids 
Figure 4.4 showed that only four out of 67 phytochemicals that were tested have 
strong and stable interactions with the target Rab5A protein (PDB I D :  1 N6H). EGCG 
A 
64 
form hydrogen bond mteractions with three amino acids - Ala30, Ser34, and Gln4 - in 
the RabSA actIve ite. El laglc acid form two hydrogen bonds with Gly32 and Glu47 
and macrocarpal A form hydrogen bonds with AlaSS, Met88, Gly92, and Ala93 while 
quercetin form tv. 0 hydrogen bond with ThrS2 and Asp7S. These amino acid re idues 
are located in the active ite of the RabSA ba ed on it interactions with GTP. 
C 
fI.·lacrocarpal A 
Figure 4 .4 :  EGCG showing hydrogen bond interactions with 3 amino acids (Gln49, 
Ser34, A la 30), B. El lagic acid showing hydrogen bond interactions with 2 amino acids 
(Glu47 and Gly32), C .  Macrocarpal A showing hydrogen bond interactions with 4 amino 
acids (Met88, Gly92, Ala93 and AlaSS), D.  Quercetin showing hydrogen bond 
interactions with 2 amino acids (ThrS2 and Asp7S) .  
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4.2.3 Root l\lean S q u a re De iation ( RJ \ 1 S D )  A n a lysis 
The analys l 'i  of molecular dynamics ( M D) s imulat ion trajectories lncluded 
phY<;lcal quant J t l e  5uch as the root mean square de\ lat ion (R 1SD), binding stabi l ity at 
thennal changes and hydrogen bond interactions showed stab i l i ty in l igand protein 
l Il teract ions along the MD s imulat ion trajectories .  RMSD of various systems reaches 
cqUlhbri L l l11 and iluctuates around the mean value at various t imes. 
1 easuring equ i l i brat ion and protein flex ibi l i ty from the starting structure is  a 
good indicat ion of stmetural tabi l i t) and s imulat ion integri ty. To measure how mueh the 
protein stmclure changes 0 er  the cour e of the s imu lat ion prote in .  RMSD duri ng the 
s lmulat i  n \vas measured. By calculat ing the RMSD value of the backbone heavy atoms 
re lat ive to the coord inates of the in i t ia l  (energy-min imized) stmc tures, the overa l l  
changes in  the  model atomic coordinates were mon i tored during MD simulations . After 
an in i t ia l  fast-rise region the RMSD values changed l i tt l e  and reached a more constant 
value. i nd icat ing that the model tructure had reached a confoID1ationai s teady state. 
C hange on the order of 1 -3 A are acceptable for smal l ,  globular prote ins whi le 
changes much larger than that, howe\ er,  indicate that the protein may be misbehaving 
during the s imu lat ion. F lexible regions e .g .  large loops, unwound termin i ,  etc. can cause 
large contributions to RMSD.  
In  RabSA, RMSD was calculated for the  protein (a l l  atoms of the protein 
backbone w ithout hydrogen) .  The overa l l  RMSD final ly  fluctuated bet\veen 1 . 5 and 2 .6  
A ( F igure 4. S ). 1 t  d id  no t  exceed 3 A i ndicat ing that the systems had equi l ibrated wel l .  
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F igure -l. S :  RMSDs of the protein backbone heavy atoms with each l i gand (EGCG, 
e l l agic ac id, macrocarpal A,  quercet in) .  
4.2.4 A n a lysis  of Hydrogen Bond I n teraction 
Hydrogen bond in teract ion with amino acids p lay an import role in  stab i l izing 
protein-l igand complexes. I t  p lays a key ro le in both the fom1ation and s tabi l i zation of 
prote in structures. They fom1 and break wh i le a prote in  defOlms, for instance dur ing the 
transi t ion from a non-functional to a functional state. In  th is  work, hydrogen bonding was 
analy:-cd along the length of the M D  s imu lation trajectories. The t ime dependence of the 
hydrogen bonds formed by the prote in  and l igand during the M D  s 1 l11Ll lat ions was 
c\ a luatcd 
67 
Hydrogen bond in teract ion  between EGCG a n d  RabSA 
M D  imulation of Rab5A with EO 0 bowed table hydrogen bonding 
throughout the Imulation penod, which i presented in  Figure 4 .6 .  EGCG fonns strong 
hydr g n b nd with thr e amino acid  G ln49, er34, A la30 with di tance 2 to 3 in  50 
n .  
I I  drog n bond ( I I ) of er34 with (0 1 1 )  of EGCG, and hydrogen bond ( H 7) of 
EGCG with the (0) atom of Gln49 bound approximately in 3 A. While other hydrogen 
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F igure 4 .6 :  I nteractions of Rab5A amino acid  res idues A .  G ln49, B . Ser34 and C. A la30 
with EGCG atoms ( H 7, 0 1 1 and 07) respectively 
B. H y d rogen bond i n teraction between el lagic acid and RabSA 
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E l lagic acid pr duced mor fl uctuation \ hen it formed hydrogen bonding 
interactIOn with G lu47 and Gly32 of Rab5 . The di  tance wa high and not table in 
the fir t 1 0  ns due to opt imizati n of interact ion with the water 01 ent. Hydrogen 
bond interaction di tance decrea e aft r 1 0  ns and was fl uctuating around 4 A for 
Gly47 and 3 for Gly32 unt i l  the end of M D  simulat ion trajectory. Figure 4.7 
i l lu trates hydrogen bond d istance between (HA) of GJu47 and (0 1 )  of el lagic ac id 
and wa fl uctuat ing around 4 A.  However, with G ly32 the hydrogen interaction 
di  tance was closer to 3 between ( HA3)  of Gly32 and (OS) of e l lagic ac id .  
Int�r3ction o f  RAB5A G l u47 ( H  ) and El lngJc Acid ( 0  I ) Interactwn or RAB5A Gly32 ( HA3) <Inti Ellngic ACid (08) 
, . 
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I �JI �1.tM\"''l/!I;�\ IvJ\'IIW.�,J\VJ lv1'f/!.1.d� 
I" ,u <" 1 
,,, 
t 11 
1 ': J \ ..... """"""M ""i.\M>J'�� w 
o· o L 1 0  10 30 Tllu': lm,1 
Figure 4 . 7 :  Interact ions of Rab5 A  amino acid residues (Glu47 and G ly32) wi th eUagic 
acid atoms (OS, and 0 1 )  
C. Hyd rogen bond i n teractions between macrocarpal  A a n d  Rab5A 
Stable hydrogen bonds formed after the first 1 5  ns i n  the s imulat ion of Rab5A 
wi th  macro carpal A .  F igure 4 .S i l lustrates that (0)  of G ly92 form hydrogen bond with 
(H37)  of macrocarpal A, which was constant around 4 A. The other hydrogen bond 




the M D  imulation .  Third hydrogen bond fomlcd between 0 atom o f  Met88 amino acid 
andH22 atom of macrocarpal A and was nearly con tant around 4 in the MD 
I nlUlation. 
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Imerae l , on or RA B 5 A  MClR8 (0) and Macrocarpal A ( H22) 
Figure 4 . 8 :  I nteract ions of RabS A  amino acid (G ly92, Ala93 and Met88)  with 
macrocarpal A atoms ( H3 7, OS,  H22)  
D. Hyd rogen bond i n teractions between q u ercetin and Rab5A 
MD s imulat ion showed that hydrogen bond interaction between querceti n  and 
RabSA was fluctuat ing around 2 A between (OD 1 )  of Asp7S and (H8 )  of querceti n  and 
, . • 
A .  
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D. Hyd rogen bond i n teractions between q u ercet in and RabSA 
MD s Imulat ion showed that hydrogen bond intcract ion betwecn quercet in and 
Rab5A \\ as fluctuat i ng around :2 A bet\\'een (OD I )  of Asp75 and ( l I 8 )  of quercetin and 
the second hydrogen bond between (03) of Th52 and (03 ) of quercet in with a distance of 
3 A in the MD s l lmdat ion as hown in F igure 4 .9  
I lllera,llon 0 1  RAUSA Asp75 (00 1 /  �n" Qucr�clm ( I I  J Illlccact.on of RAB5A Thr52 (03 ) ".lh Quercetin (03 1 
T T T r --
" 
T..mc lr.!i) Tim..: r�) 
B .  
F igure 4 .9 : Interactions of Rab5 A  amino acid  residues (Asp75 and Thr52)  with quercet in 
atoms CB8 and 03 ) 
-t.3 EGFR as  second promis ing ta rget 
The second most promising target was EGFR in th i s  study (PDB ID :  3 W2S) .  
EGFR i s  im oh ed in the patbogenesi and progress ion of di fferent carcinoma types. Most 
l i gands d id not show any good i nteract ion with EGFR except for one extracted from 
c i trus frui ts  cal led hesperid in .  It showed strong hydrophobic interaction and good 
hy drogen bond interact ions based on molecular docking and M D  simulat ion.  
Furthermore, hesperidin didn't show any tox ic i ty risk in ADrvl ET ana lysis .  
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4.3. 1 Molecu lar  Docking  
The analy J of EGFR molecular docking did not produce any good re u l t  with 
rno t of the phytochemical . th only one that shows good and stable interaction was 
he peridin. LIGPLOT analy i howed that it ha interactions with several amino acid 
re idues - Phe723, Gly724, Cy 797, A p837 and Arg84 1 as hown in F igure 4 . 1 0 . 
Previou studie have found that Cys797 i critical for l igand binding to EGFR 
(Zhong et aI., 2009). Drug like gefitinib and erlotinib have been used in patients with 
either wild- type or mutant EGFR. EGFR was found to be more sensitive to erlotinib than 
to gefitinib. Their docking studies suggest that Cys797 could be the key residue 
re pon ible for the enhanced sensitivity of erlotinib. It impl ies that Cys797 should be 
taken into account in drug de ign targeting the EGFR. Two point mutations resistant to 
both gefitinib and erlotinib have been documented as T790M and D76 1 Y. (Zhong et aL, 
2009) 
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Figure 4 . 1 0 : LIGPLOT result of EGFR with hesperdin (PDB ID:  3W2S) 
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4.3.2 \lolecular Dyna mic i m u lation 
MD Imulation howed that he peridin remained tably bound in i ts binding ite. 
Many amino aCId were invol ed in the strong binding to her peri din including Phe723, 
Gly724, G ly72 L Gly7 1 9, Leu7 l 8  and Cy 797 as shown in Figure 4 . 1 1 iewed in VMD. 
Figure 4 1 1 : He peridin bounded to the active sites of EGFR viewed in VMD 
4.3.3 Root Mean Square Deviat ion (RM SD) A nalysis 
10 EGFR, the overall RMSD finally fluctuated between 1 .5 and 2 .6  A, and didn't 
exceed 3 A, indicating that the system had stabil ized as shown in Figure 4. 1 2  
RMSD of EGFR and Hesperidin 





Figure 4. 1 2 :RMSDs of Hesperidin core evaluated with respect to the crystal structure 
along the M D  trajectories. 
A 
4.3.4 naly i of Hyd rogen Bond I n teractions 
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1 1  protein- l igand atom hydrogen bond interactions had a d istance between 2 to 
-+ a 110\\ n i n  Figure  4 . 1 . H drogen atom of re idue Phc723 of EGFR and (0 1 3 ) of 
he pcrid in  bo\\ ed a fluctuat ing interact ion within 2 . Leu 1 8  residue fom1ed hydrogen 
bond \\ l th (H 1 )  atom of he peridin within the fi r t 5 ns and was then table at 2 A. 
Gly724 (0) formed a hydrogen bond wi th ( H29) of he pcrid in  and was table at 3 A for 
mo t of the imulat ion. Hydrogen bond in teraction formed between ( H )  atom of Cys97 
and 06 of h pcrid in fluctuat d b tween 2 and 4 . While n i trogen atom of Gly7 1 9  
fomled hydrogen bond with ( H I )  of he perid in after around 1 0  ns and fluctuated at a 
d i  tance of 4 
Intt:raClH.)n uf EGFR Phc723 ( H l  and HL""!.penuin (0 1 3 ) 
J. TIIII� ''''' 
InlernClIon of EGFR Leu7 1 8  (0) and He'peridln (H I I  
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j : 11\ 1 
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F igure 4 . 1 3 :  I nteract ions of Rab5A amino acid  res idues ( Phe723 ,  Leu7 I 8 , Gly724, 
Cys797 and G ly7 1 9) with l igand atoms (0 1 3 , H 1 ,  H 29, 06, and H I )  
4 .4 Toxic ity and Solu b i l ity of Ligands 
Characterization of  Absorption, Distribution, Metabo l ism, Excretion, and 
Tox ic ity (ADMET) propert Ies \\ erc predicted using ill siLica methods to knO\\ whether 
the phytochemicals have the potential  of ad\ ersely affect ing humans. This i nc ludes 
propert ies l i ke mutagenic tU l11orog(:nic i ty ,  i rr i tant or reproduct i \e  effects as predicted by 
the Osir is  Property Explorer ( F igure -1- . 1 4 ) .  
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Figure 4 . 1 4 :ADMET properties showed the toxicity risks of for EGCG, eUagic Acid, 
macro carpal A quercetin and hesperidin 
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The toxicity risk propert ies or the ones that that have side effects l ike 
mutagenicity or poor intestinal absorption are shown in red. Green color indicates that 
the properties are acceptable. El lagic acid, EGCG and hesperidin did not show any 
toxicity risks (mutagenic, tumorigenicity, irritant or reproductive effects). However 
macrocarpal A howed high risk effect in tumorigenicity and irritant effect, whi le 
mutagenic and tumorigenicity effect was high for Quercetin. 
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Para meters H esperid in  EGCG E l lagic l\1 acrocarpal Quercetin Acceptable 
acid A range 
Calcu lated -0.0 1 2 .05 1 .28 5 .36  1 .49 -0.7 to 5 .0 
LogP Coclanol/Cwalcr 
Sol ub i l i f! -2 75 -2 . 1 6  -3 .29 - 5 . 5  -2.49 o to -6 mol L 
( Log ) 
Molec u l a r  6 1 0  458 302 472 302 < 500 g/mol 
'Weight 
TPSA 23-1. .2  1 97 1 3 3 . 5  1 1 5 1 27 .4  20 t o  1 30 A2 
Drugl i kenes 3 .46 1 .5 8  - 1 .6 -4. 1 1 .6 >0 
s 
Drug Score 0 5 7 0 .7  0 .5 1 0.07 0.3 0 - 1 
Table 4 . 3 :  ADMET re u l ts  compared to the preferred range of values 
The 10gP \'a lue of a compound, which is the logarithm of i t s  part i t ion coefficient 
betv, ecn n-octanol and water (Coclano/C"3lcr) ,  i a wel l -establ i shed measure of the 
compound' hydropbi l i c i ty .  I t  has becn shown for compounds to have a reasonable 
probabi l i ty of being wel l  absorb i f  the ir  10gP value must  not be greater than 5 .0 and 
smal ler than -0 . 7 . Low hydroph i l ic i t ies and therefore h igh logP values cause poor 
absorpt ion or pem1eat ion.  As shown in Table  4 .3  a l l  l i gands showed acceptable range, 
on ly marcorcarpal A showed a s l ight out of range va lue for 10gP (5 .36) .  
The aqueou solubi l i ty of a compound s ignificantly affects i ts absorption and 
d Istribution characteri st ics .  Typical ly, a lov. solub i l i ty goes a long with a bad absorption 
and therefore the general aim is to avoid poorly soluble compounds. As shown in Table 
4 .3 .  macrocarpal A had bad absorption ( logP- 5 . 36) and low o lub i l i ty ( logS= -5 .5 
mol/L )  u n l i ke othcr l i gands . 
Molecular wcight on the other hand opt im izes compounds for h igh act Iv i ty on a 
b IO logical target . Th is  property usua l ly  rcduces with increased molecular weIght .  
Compounds \\ ith h igher wcights m e  less l l kc ly  to  b e  absllrbcd amI there rore to e\ c r  reach 
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the place or act ion. Thus, keepmg molecular weights as low as possible 1 desirable .  Only 
hesperid in  had a sl ight l y  h igh molecular \\ eIght in the short l i sted chelll lcais .  
Topolog Ica l  Molecular Polar urCace Area (TPSA) calculates the um of surface 
contribution of polar atoms (e.g. oXygens, ni trogens and hydrogens) in  a molecu le .  This 
con-e l ates \\ el l  with drug transport propert ies, such as i ntestinal absorption, or blood­
bra ll1 ban-ier penetrat ion.  Hesperid in and EGCG showed a s l ight ly h igher TPSA 
compared to the other l igand . 
A posi t l \  e value for Drug l ikeness i ndicates that the molecule contains 
predominant ly fragments, which are frequently present in  commercia l  drugs. A molecule 
wIth h igh dmg l ikeness score may not rea l ly qua l ify for bei ng a drug because of i ts  high 
l tpophi l ic i ty .  Only e l lagic acid and macrocarpa l A hawed negative score in  this case. 
The DmgScore combines cLogP, Solub i l i ty ( logS), molecular weight ,  
Topological Molecular Polar Surface Area (TPSA),  drug l ikeness, dmg and tox ic i ty risks 
to j udge tbe compound's overa l l  potent ia l  to qua l ify as a drug. Table 4.3 shows that the 
o\'era l l  score i s  below 1 for a l l  tbe short l i sted compounds indicating that they may be 
good candidate drugs. 
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C h a pter 5 :  Discuss ion and Conclus ion  
Many drugs are smal l  molecules ( l igands ) that bind t o  the active s i te o f  specific 
targets (proteins )  Therefore, Idcntification of  l igands that  bind to these prote ins using 
protein- l igand dock ing is an important step in structure-based drug design. 
The o\ cra l l  research goal of this project was to understand the atomic level 
intcract lons between a l i 't of ph)10chemical l igand and receptor proteins based on their 
b 1 l1d ing mode and to e lect a fe\\ candidate l igands for cancer therapy using in silica 
methods l ike molecular dock ing and M D  s imu lat ion. 
5. 1 Molecu lar  Docking 
7 d ifferent proteins were selected and 67 d i fferent phytochemicals, known to have 
mechanism of action as anticancer compounds, v. ere docked with these proteins .  Two 
promis ing target protein - Rab5A and EGFR - showed good hydrogen and hydrophobic 
in teract ions wi th some of the chemica ls  chosen. 
Rab5A PDB I D :  1 6L)  structure complexed with GTP in  the act ive site (Scr 29, 
Gly 32, Lys 33, Ser 34, Ser 35 ,  Thr 52, Gly 78, Asn 1 33 ,  Asp 1 36,  Ala 1 64 and Lys 1 65 )  
was compared with l igands docked t o  the apo Rab5A structure ( P D B  ID: I N6H) .  
L igands shared the same act ive s i te pos i t ion ( Ser29, Ser34, Thr52,  Asn 1 33 ,  Ala 1 64 and 
Lys 1 65 )  support ing thc resul ts .  Several phytochemicals l i ke anacardic acid, chlorogenic 
ac id.cyanid in .  delph in id in , e l lagic ac id .  EGCG, emodin, macrocarpal A, myrciaphenone 
8 , quercetin,  rosmarinyl glucosid and thcatlavin docked to the Rab5A act ive si te .  
L IGPLOT resu l ts showed EGFR bound cl laglc acid, hesperid in ,  i sorhamnetin. 
8 1  
myrciaphenoneB and rosmarinyl g lucoside. The docking showed that l igands bounded to 
the known active s I te ,  Phc723,  Gly724, Cys797, Asp 837 .  
5.2 ;\ID S i m u lation 
In order to confirm the binding mode of l igands and to study the dynamics of the 
EGFR and Rab5A truc(ures complexed with phytochemicals, MD simulations were 
perf 01111 cd using A M BER.  D i fferences in s tab i l i ty and dynamics among the structure of  
the  protein \\ ere obsen ed. The resul t  showed that only 4 ou t  of 67 phytochemicals 
( EGCG, e l lagic acid, macrocarpal A and quercet in) tested showed strong and stable 
i nteractions with RabS A (PDB I D :  6 H )  and 1 p hytochemical  had good interaction 
wi th  EGF R  (hesperidin) .  
To explore the dynamic stab i l i ty of protein- l igand complexes and to ensure the 
rationa l i ty of  the sampl ing method, RMSDs of RabSA and EGFR simulations were 
fOlmd. RMSD is a parameter indicating the stab i l ity of the entire protein in t ime. 
Calculating the RMSD val ues of both protein atoms showed that this was between 1 . S 
and 2 . 6  A. \vhich was with in the acceptable  range. RMS D  values from M D  simulation 
proved that the s imulation systems had reached equi l ibrium and that the prote in- l igand 
complexes were stable along the enti rety of the s imulation. 
Hydrogen bond stab i l i ty was moni tored in both docking studies and M D  
s imulat ions.  Hydrogen bond distance of RabSA fluctuated between 2 and 4 A for the [our 
l i gands (EGCG, el lagic acid. macrocarpal A and quercetin) .  EGFR a lso showed good 
hydrogen bond interactions wi th hesperidin varying from 2 to 4 A. 
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5.3 A D M E  and To x i c i ty 
1 1  the compound :>tudied are of natura l  origin and regularly consumed in human 
d Ie t .  Ho\\C \ er, both AD�lE  and toxic i ty flsk propert i es \\ ere evaluated. The mcral l  drug 
score showed that it \\ as \\ith in  the acceptable range [or a l l  the short l isted l igands. 
l I ence, these compounds could be considered as potent lead compounds against cancer. 
I l owe\ er, th is  \\ auld nced to be confirmed in lab experiments. 
504 Recom mendation fOl '  Future Research 
The fol lO\\ ing cou ld be done to extend the results from the current study: 
I .  Obta in ing l i st o[ d i ffercnt structures of Rab5A and EGFR to compare molecular 
docking and M D  s imulation re u l t  with each protein .  
2 .  1 0lecular mode l l i ng resul ts us ing Rab5A and EGF R  proteins could be tested in  vitro 
and in vim to confiml the effect iveness of  using the chemica ls  as drugs. 
5.5 L i m itat ion of the study 
The major l im i tations of th is  tudy are : 
1 .  Due to l im i ted resources, only 7 proteins  and 67 phytochemicals could be u ed i n  th is  
study. 
2 .  In silica studies prO\ ided a short l i st of potential chemicals .  However, this would 
need to be con fi mlcd with 'v\ ct lab experiments and finally in  c l in ica l  tr ials .  
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5.6 S u m m a r� 
In  th is  proJect, a selectIOn of  natural molecules was screened in silica to identify i f  
they could interact with prote ins in d in�rent cancer pathways. V i rtual crecning and 
s imulat ion. were used to obta in a short list of  candidate molecules that have potential to 
be ll cd for cancer therap} . 
T Il lS  study aimed to ans\<\ er four v i ta l  quest ions: 
J .  Doc rbc se lected chemicals form good interact ions with the chosen protein? 
2. I f  It binds. does i t  b ind to the act ive s i te of the protein or at random locations? 
3. I f  it was in the act ive s i te, does i t  b ind t ightly and stably or could it be detached 
eas i ly? 
-+ .  Does the chosen chemicals have any risk making it unsuitable for h umans? 
:'101ecular docking and MD s imulations were emp loyed to study if the l igands 
would remain stable  in the bound state. A comparison of the docking results with 
prevIOus mdies i nvolving act ive s i te amino acid residues confirmed that the 
phytochemical l igands bound to the active s i te of  the two target protei n  - Rab5A and 
EGFR.  Furthemlore, s imulation resul ts showed that only four l igands remained stable in 
s imulations which were EGCG, e l lagic Acid,  macrocarpal A and quercetin for Rab5A 
and hesperid in  for EGFR.  
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